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Summary 
 
Although neurotransplantation of primary fetal cells into the striatum of patients with 
Parkinson’s disease (PD) has been reported to be effective, poor clinical outcome 
and severe side effects lower clinical long-term results. A major drawback of cell 
replacement therapies in PD is the low cell survival and lacking regeneration of the 
neuronal circuitries due to the ectopic transplantation of cells into the host striatum. 
More anatomic and functional integration could potentially be reached by an 
orthotopic cell transplantation into their natural position within the rostral 
mesencephalon at the site of the substantia nigra, where dopaminergic cells get lost 
in PD. The aim of the thesis was to provide the scientific basis for the use of 
injectable bioscaffols containing chemo-attractants promoting cell survival, 
differentiation and axo-dendritic outgrowth of dopaminergic cells. With the so called 
“bridging” transplantation technology an artificial axon pathway between the 
substantia nigra and the striatum with targeted nigro-striatal re-innervation should be 
generated. Thereby, the central dopaminergic nigro-striatal pathway would be 
reconstructed enabling a fully integration of grafted neurons into the basal ganglia 
circuitries.  
The main focus of the thesis was to explore the influence of bioscaffolds on 
cell survival and morphology of dopaminergic neurons in vitro. The investigations 
included isolation of primary fetal mesencephalic cells and fetal mesencephalic 
neural stem cells (NSCs) from embryonic (E14) mouse brain and their culture on 
ECM compounds and starPEG-heparin hydrogels. Initial characterizations of the gels 
showed separate as well as simultaneous immobilization and release of growth 
factors demonstrating that hydrogels could serve as an efficient storage and delivery 
system for growth factors. The axo-dendritic outgrowth of dopaminergic cells 
including primary branching, total branching and neurite elongation; cell survival 
studies; cell type analysis and cell migration were analyzed by immunostaining.  
Both cell sources showed distinct growth properties depending on the stiffness 
of the gel material and the presence of biomolecules with increased cell survival by 
the presence of RGD and FGF-2 in the hydrogel independent of network 
characteristic. Moreover, the presence of RGD on hydrogels was found to initiate 
differentiation of NSCs, whereas FGF-2 bound to hydrogels was shown to promote 
the viability of undifferentiated cells. Additionally, survival and axo-dendritic outgrowth 
of dopaminergic cells were observed to be affected by the gel properties: RGD or 
FGF-2 modification of hydrogels with intermediate network density showed the best 
results for dopaminergic growth. With the addition of GDNF to hydrogels the total 
amount of cells decreased strongly by an equal quantity of dead cells compared to 
FGF-2 bound hydrogels. Furthermore, differential effects were found for the survival 
of different brain cells depending on the growth factor which is loaded. GDNF was 
found to increase the survival of astrocytes, whereas FGF-2 bound to gels stimulated 
the viability of oligodendrocyte precursor cells. No differential effects were found for 
the survival of NSCs and mature neuronal cells on GDNF or FGF-2 bound gels.  
By showing the penetration of primary fetal mesencephalic cells expressing 
MMPs as endogenous endopeptidases into MMP-cleavable hydrogels, the potential 
biodegradability of the starPEG-heparin hydrogels was demonstrated.  
Together the findings provide the in vitro proof-of-principle data for combining 
dopaminergic neurons or predopaminergic NSCs with biomaterials for reconstructing 
the central dopaminergic nigro-striatal pathway by the “bridging” transplantation 
strategy as an alternative transplantation approach in PD. Further studies should 
focus on three-dimensional cell culture studies using starPEG-heparin hydrogels with 
cleavable peptide sequences and their functionalization with gradients of axon 
guidance molecules to selectively promote dopaminergic outgrowth.  
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1. Introduction 
 
1.1 Tissue engineering and regenerative medicine 
The generation of tissue, organs or even complex organisms was for a long time a 
vision of mankind throughout the history of medicine. Until today a lot of pioneering 
work is done to generate or regenerate tissue and organs. First bioengineered 
products are applied in the clinical reality and much more are in preclinical stage. The 
terms tissue engineering and regenerative medicine are nowadays considered as an 
approach to generate complex tissue and organs from simple parts. While tissue 
engineering more address the technical concept of reconstructing tissue and organs 
with the help of cells, biomolecules and scaffolds, the term regenerative medicine is 
more focused on the support of self healing abilities and on the use of stem cells. In 
this young field of biotechnology various scientific disciplines such as biochemistry, 
cell biology, pharmacology, material science, engineering and clinical disciplines are 
closely connected and all tracing the same intention of regenerating damaged tissue 
by implanting cells in combination with scaffolds. On this way several challenges 
need to be met concerning scientific, technological, clinical, ethical, and also social 
issues.  
Fundamental for tissue engineering is a successful in vitro cultivation of cells. 
A breakthrough was reached by Ross G. Harrison in 1907 demonstrating active 
growth of nerve fibers in vitro. He was a pioneer who first successfully overcame 
basic culture problems and created a technique for other scientists. In 1935, Alexis 
Carrel and Charles Lindbergh published the book “The Culture of Whole Organs” 
describing the ex vivo culture technique for organs including the use of a perfusion 
pump [1]. In the early and mid 20th century lots of successful transplantations of many 
organs followed. However, organ transplantation as a long-term solution is a life-
saving therapy with many clinical problems concerning a limited supply of donor 
organs/tissue, the possibility of rejection and the use for long-term 
immunosuppression. Tissue engineering strategies will ideally overcome these 
difficulties.  
The first synthetic polymeric material based on poly(vinyl chloride) were 
grafted together with endothelial cells in dogs to replace aortic segments [2]. A similar 
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approach by William Chick and his colleagues involved seeding pancreatic beta cells 
on a semipermeable membrane [3]. Thus, living and artificial components were 
combined and used to successfully treat diabetes in rats [4] and dogs [5]. In the early 
1970s W.T. Green studied cartilage formation in vitro and in vivo using a chondrocyte 
culture technique in combination with specifically tailored scaffolds [6]. Despite of his 
inability to generate new cartilage, he established the theoretical and practical 
concept of combining cells with scaffolds. With the first in vitro cell-scaffold approach 
described by John Burke and Ioannis Yannas in 1981 the generation of skin by a 
culture of dermal fibroblasts and keratinocytes on a collagen and silicon based 
material was an innovation in regeneration of burn wounds [7]. With this dermal 
template they could encourage the ingrowth of native skin and vessels from the 
surrounding skin. A similar approach used in vitro expanded autologous dermal 
fibroblast and epidermal keratinocytes seeded on a collagen matrix to generate a full 
thickness skin graft [8]. Within the scientific community the term and the field tissue 
engineering was on the way to become established. Publication of an article by 
Joseph Vacanti and Robert Langer in Science in 1993 was a key point in tissue 
engineering introducing the field to a broader scientific community and  describing the 
new technology with all critical areas [9]. It is referenced as the beginning of this new 
biomedical discipline.  
As the use of extracellular matrix (ECM) has led to a number of exciting 
advances in tissue engineering, the use of biological scaffolds deserved closer 
attention. Now, ECM-based strategies with decellularized matrix products engineered 
from various parts of the human body were combined with autologous cells to 
regenerate patient-specific tissues [10, 11]. For this strategy the supply of available 
materials is also limited relative to solutions using synthetic biomaterials. Therefore, 
the development of functional synthetic extracellular matrices may further reduce the 
need for donor tissue.  
Essential for tissue engineering is beside generation of a proper bioscaffold a 
well-characterized, easy accessible cell population. In addition ideal growth factor or 
conditioning regimes for differentiation and maintenance of differentiated stage are 
required. While the use of embryonic stem (ES) cells for tissue engineering strategies 
is hampered by ethical concerns as well as the fact that ES cells are more prone to 
favor tumor or teratoma progression, the identification and the use of other cell 
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sources like adult stem cells and induced pluripotent stem cells is a promising 
strategy. Furthermore, the use of autologous tissue for transplantation eliminates the 
need of immunosuppression. With their successful cultivation and their capability to 
differentiate into different cell types they are a prospective cell source for cell 
replacement therapies. 
 
1.2 Restorative treatments for Parkinson’s disease 
1.2.1 Main aspects of Parkinson’s disease and available therapies 
Parkinson’s disease (PD) is a chronic, slow progressive neurodegenerative disorder 
of the central nervous system. Due to the selective loss of dopaminergic (DAergic) 
neurons within the substantia nigra in the midbrain the dopamine release in the target 
region – the striatum – is strongly reduced. Under healthy conditions DAergic cells 
project their axons from the substantia nigra via the nigro-striatal pathway to the 
striatum, where an extensively branching takes place and the neurotransmitter 
dopamine is released. The death of these cell type results in the degeneration of 
axonal projections into the striatum, and thus the nigro-striatal pathway is destroyed. 
Several motor symptoms, such as rigidity, tremor and bradykinesia as well as non-
motor symptoms like disabilities of speech, cognition, mood, and behavior are a 
result of the destroyed nigro-striatal pathway in PD patients. The reasons for this 
continuous and selective loss of DAergic neurons still remain unclear. The absence 
of enzymes, neurotransmitters, trophic factors or the existence of toxic factors or 
physical injuries may play a role at the onset and the progression of PD.  
Current therapies for PD are primarily based on pharmacological replacement 
of lost striatal dopamine by Levodopa administration, which subsequently improves 
motor symptoms [12, 13]. These approaches remarkably moderate PD symptoms, 
especially in early stages of the disease [12, 13]. At progressive stages of disorder 
the efficacy of these therapy declines and many patients develop drug-induced 
dyskinesia. Therefore, electrical deep brain stimulation in the Nucleus subthalamicus 
was developed [12, 14, 15]. This treatment alleviates only some of the symptoms 
resulting from a partial normalization of the neuronal activity. So far, these therapies 
are only symptomatic treatments of the nigro-striatal deficit associated with PD. 
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Hence, the need for an improved long-term treatment is evident. A possible strategy 
is to restore the lost neuronal subtype by cell transplantation. 
 
1.2.2 Stem cell-based cell sources for cell replacement therapies in PD 
Neural transplantation in PD is based on a well-defined biological mechanism: 
Recovery of function by restoration of dopaminergic transmission in the striatum. 
Possible cell sources for cell replacement therapies in PD are fetal primary tissue, 
fetal neural stem cells (NSCs), embryonic stem (ES) cells, induced pluripotent stem 
(iPS) cells, adult brain-derived stem cells and adult multipotent stem cells [16].  
NSCs are multipotent stem cells derived from the nervous system with 
regenerative capacity. They can differentiate into all three major cell lineages of the 
nervous system: astrocytes, oligodendrocytes and neurons [17-20]. An initial study 
for in vitro culturing of NSCs showed that fibroblast growth factor-2 (FGF-2) 
stimulates the proliferation of rat neuronal precursor cells [21]. Furthermore, the 
induction of the growth of striatal precursors retaining their capability to differentiate 
into all major cell lineages has been demonstrated [22]. Since these studies two 
mitogens (EGF and FGF-2) were used for the in vitro proliferation of fetal NSCs [23]. 
For generating DAergic neurons, the differentiation of mesencephalic NSCs in vitro 
by specific growth factors or cytokines activating the expression of transcription 
factors, such as Nurr1 and Pitx3, is necessary [17]. For the expansion of 
mesencephalic NSCs from rodents and human over a long-term period and with 
stable growth behavior and apoptosis rate a level of 3 % oxygen is necessary [24-
27]. However, long-term survival and phenotype stability of DAergic neurons 
generated from fetal NSCs after transplantation in animal models of PD still have to 
be demonstrated. The low tumorigenic formation of fetal NSCs in comparison to ES 
cells, immortalized cell sources and iPS cells seems to be a major advantage, 
whereas their low expansion and differentiation as well as ethical concerns limit their 
use for cell replacement therapies.  
Human ES cells with their characteristics of self-renewal and pluripotency 
differentiating in any of the three germ layers seem to be a reliable cell source. Prior 
to transplantation into animals models of PD ES cells were differentiated in vitro into 
neural precursors [28] or DA neurons [29, 30] showing in some cases a partially 
functional recovery. Using ES cells in cell replacement therapy in PD, there is the 
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problem of controlling cell growth and differentiation. In most studies using ES cells 
for transplantation brain tumor or teratoma formation and a low graft survival were 
reported [31-34]. 
The pioneering work of Takahashi and Yamanaka in 2006 generating iPS cells 
from mouse fibroblast afford a new opportunity to generate cells with characteristics 
of ES cells [35]. Neurons derived from reprogrammed mouse fibroblasts functionally 
integrate into the fetal brain and improve symptoms of rats with Parkinson's disease 
[36]. As an autologous cell source, patient specific iPS cells exhibit an interesting tool 
for regenerative cell therapy approaches due to no ethical concerns and no needed 
immunosuppression. Moreover, their differentiation into DA neurons in vitro could be 
shown recently [37]. The growth of differentiated Parkinson patient-derived iPS cells 
in the adult rodent brain without signs of neurodegeneration and a reduction of motor 
asymmetry in Parkinsonian rats were reported [38]. For the generation of iPS cells 
most of the reprogramming strategies are using viral transfection of putative 
oncogenes, which my cause cancer by integrating into the genome. The use of 
adenovirus [39], plasmids [40] and recombinant proteins [41], [42] could be an 
alternative way for reprogramming. However, a lot of hurdles have to be taken before 
the iPS strategy can be used for clinical applications.  
 
1.2.3  Cell transplantation strategies for Parkinson’s disease 
Clinical trials of neurotransplantation using human mesencephalic DAergic neurons 
provided the proof-of-principle for dopaminergic cell replacement strategies [43, 44]. 
The main transplantation studies have focused on re-innervating the striatum by 
ectopic placement of DAergic grafts (Figure 1A). PET scans and postmortem studies 
showed that DAergic neurons implanted into the striatum of patients with PD survive 
and re-innervate the striatum. Although ectopic transplantation has demonstrated a 
successful method of integration of implanted DAergic neurons into the host striatum, 
only a subset of younger patients showed clinical benefits [43]. Furthermore, in 
another double-blinded, placebo controlled (sham surgery) trial of bilateral fetal tissue 
transplantation fifty-six percent of transplanted patients suffered from severe 
dyskinesia after overnight withdrawal of dopaminergic medication [44]. Some patients 
could benefit from the transplantation of human fetal cells [34, 45] but limited tissue 
availability as well as ethical concerns requires alternative cellular sources.  
Introduction 
___________________________________________________________________________ 
___________________________________________________________________ 
 
- 13 - 
As ectopic transplantation of primary fetal cells into the striatum exhibits only 
poor clinical outcome and severe side effects further progress had to be done in the 
development of an alternative transplantation strategy in PD. More anatomic and 
functional integration could be reached by an orthotopic cell transplantation into the 
natural position within the rostral mesencephalon (Figure 1B) [46]. Therefore, the 
main focus is the reconstruction of the nigro-striatal pathway to enable a fully 
integration of grafted neurons into the basal ganglia circuitries. The feasibility and 
safety of intranigral transplantation have been shown in rodents [47-50] and humans 
[51, 52]. Graft integration, survival and partial functional recovery have been 
demonstrated and allow the assumption for the existence of factors guiding targeted 
nerve fiber outgrowth from the substantia nigra to the striatum [47-50]. Recently, 
anatomical and functional reconstruction of the nigro-striatal DAergic pathway by 
intranigral transplantation of fetal cells has been demonstrated for the first time [53, 
54]. With the so called “bridging” technology an artificial axonal pathway between 
Substantia nigra and striatum with targeted nigro-striatal re-innervation is generated 
by growth factors, other cell types or chemicals using primary DAergic cells [50, 55, 
56]. One of these transplantation studies used kainic acid, an excitatory amino acid, 
as bridging molecule [50]. Similar results were shown using kidney tissue as bridging 
tissue, known to produce high amounts of glial cell line-derived neurotrophic factor 
(GDNF). Tyrosine hydroxylase (TH) positive fiber tracts from the Substantia nigra re-
innervate the striatum in hemi-parkinsonian rats [55]. In both studies, a trophic 
environment could be triggered by the bridging materials guiding effectively 
transplanted neurons to send axons through the track innervating the distal striatum 
and thus to restore the nigro-striatal pathway. Together, a successful reconstruction 
of the nigro-striatal pathway in PD animal models could be shown using the “bridging” 
strategy. Major concerns still exist about the used bridging material. For an 
application in humans the development of another source of material with controlled 
release of neurotrophic factors, improved survival of DAergic neurons, as well as 
promoted growth of their axons are indispensable. 
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Figure 1: Cell transplantation strategies in Parkinson’s disease. (A) As a conventional 
strategy cells are transplanted ectopically in the striatum. The dotted areas highlight the lost 
DAergic neurons in the Substantia nigra and the degenerated nigro-striatal pathway resulting 
in a reduced innervation of dopaminergic axons in the striatum. (B) With the “bridging” 
strategy cells are transplanted in the Substantia nigra and the nigro-striatal pathway is 
reconstructed by implantation of a biomaterial promoting cell survival in the Substantia nigra 
as wells as axo-dendritic outgrowth to re-innervate the striatum. Thus, a more anatomic and 
functional integration could be achieved (modified from [57]). 
 
1.2.4  Potent growth factors promoting survival and axo-dendritic outgrowth of 
DAergic neurons  
Growth factors are steroid hormones or proteins stimulating cell growth, proliferation 
and differentiation. They are important for regulating a variety of cellular processes. 
Such signaling molecules are secreted and bind to specific transmembrane receptors 
on the surface of their target cells. Acting as growth factors the neurotrophic factors 
are important for promoting growth and differentiation of neurons during development 
as well as phenotypic maintenance of adult mature neurons. In PD neurotrophic 
factors provide important therapeutic effects by promoting the survival of DAergic 
neurons and protecting this specific cell type after administration of dopamine neuron 
death inducing toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridne (MPTP) 
and 6-hydroxydopamine (6-OHDA). Furthermore, they are able to restore the function 
of moribund DAergic neurons by changing the gene expression and protein synthesis 
and may stimulate the dopaminergic system by affecting the ion channels leading to 
modifications in cell excitability for instance [58].  
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Neurotrophic factor are classified into several families of structurally and 
functionally related molecules: (1) Nerve growth factor (NGF)-superfamily; (2) glial 
cell line-derived neurotrophic factor (GDNF) family; (3) neurokine or neuropoietin 
superfamily; (4) non-neuronal growth factor-superfamily [59]. Several factors are 
considered as potential therapeutic molecules for therapies in PD. The survival of 
embryonic DAergic neurons in vitro and in vivo have been demonstrated for some 
neurotrophic factors as well as non-neuronal growth factors including brain-derived 
neurotrophic factor (BDNF) [60], neurotrophin-3 (NT-3) [61], neurotrophin-4/5 (NT-
4/5) [62], GDNF [63, 64], transforming growth factor-beta (TGF-ß) [65, 66], insulin-
like growth factor (IGF-1) [67], epidermal growth factor (EGF) [68] and both acidic 
fibroblast growth factor (aFGF/FGF-1) and basic fibroblast growth factor (bFGF/FGF-
2) [69-71]. Recently, a new family of neurotrophic factors containing cerebral 
dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived 
neurotrophic factor (MANF) have been reported protecting midbrain DAergic neurons 
[72, 73]. 
Besides promoting survival of DAergic neurons axo-dendritic guidance cues 
could be conductive for reconstruction of the nigro-striatal pathway. For many 
neurotrophic factors, such as GDNF [64, 74], NT3 and BDNF [75], an axo-dendritic 
growth promoting effect on DAergic neurons had been shown. Recently, several 
other factors including Slit-1 and -2 [76]; Netrin-1 [77]; ephrin-a [78, 79] and 
semaphorins [80, 81] had been identified to play a role for midbrain DAergic axon 
pathfinding. Netrin-1 and Sonic hedgehog (Shh) act as a chemoattractant molecule 
for midbrain DA neurons in vitro [77, 82].  
 
1.2.5 Strategies for GDNF and FGF-2 delivery to the brain 
Since GDNF has protective, restorative and axonal promoting properties, this 
promising molecule has been studied extensively in vitro as well as in animal models 
of PD. Human GDNF gene encodes for a 134 amino acid mature protein forming a 
two15 kDa disulfide-linked homodimeric glycoprotein. Large size of the protein, 
chemical structure and fast degradation makes the entry into the CNS through the 
blood-brain barrier (BBB) impossible.  
Different methods for the delivery of trophic factors to the CNS were applied 
bypassing the BBB. Although intracerebroventricular delivery of GDNF increased the 
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number of DA neurons in the midbrain of MPTP depleted monkeys, this method was 
not successful in humans [83, 84]. It is extremely likely, that the diffusion of the factor 
from the ventricular ependyma to the putamen through the much larger human brain 
is not possible. 
Another delivery method into the striatum is the direct infusion of trophic factor 
with minipumps [85]. An advantage of this administration is the complete control of 
the delivered dose, but the limited diffusion of the protein resulting in a concentration 
gradient generated at the point of infusion and thus the use of higher concentration of 
neurotrophic factor is a major limitation of this delivery method. Therefore, high 
concentrations of the neurotrophic factor as well as pump refilling are needed.  
Constant and local in situ expression of GDNF can be achieved by 
recombinant viral transduction [86]. Adenovirus (AV), adeno-associated virus (AAV) 
and lentivirus (LV) have been successfully tested for durable expression of GDNF in 
animal models of PD [87-89]. As a proof-of-principle, Bilang-Bleuel A. and coworkers 
have been demonstrated the prevention of DA neuron degeneration by intrastriatal 
injection of AV vectors expressing GDNF in 6-OHDA lesioned rats [87]. Concerns 
about the induction of a strong immune response directed the focus to AAV as well 
as LV vector systems for in vivo gene delivery. Both strategies showed promising 
results [89, 90] but the risk of tumor formation limit the application of lentiviral vectors. 
So far, AAV-mediated gene delivery seems to be the most powerful system, but 
concerns about the exact GDNF amount produced from the viral-infected neurons as 
well as control over the temporal gene expression still remain.  
An alternative gene therapy approach to circumvent concerns about the direct 
injection of viral vectors into the brain is the ex vivo gene transfer of GDNF and 
encapsulated cells. The most promising cell source for ex vivo gene transfer are 
NSCs which can be differentiated into a particular neuron cell type and do not form 
any teratomas. The main risk for transplantation of genetically engineered cells is that 
the cells can be rejected by the immune system of the host. Therefore, the cells have 
to be encapsulated into macro- or microcapsules. The encapsulating material should 
allow the diffusion of nutrients from the brain to the cells and vice versa the secretion 
of trophic factors. An 8-week survival time of genetically modified cells producing 
GDNF in the striatum of 6-OHDA parkinsonian rats and protection of the dopamine 
system has been demonstrated [91]. A major drawback of using capsules is that the 
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minipores can become blogged resulting in an insufficient supply of nutrients to the 
cells which can cause the death of the encapsulated cells. 
Another strategy for slow GDNF delivery is the use of drug-releasing 
biocompatible, biodegradable and non-toxic polymer-based compounds. This has 
been tested for microspheres made of poly(lactic-co-glycolic) acid (PLGA) polymer 
[92-95]. GDNF has been successfully encapsulated into PLGA microspheres and 
were released in a controlled manner over long time in the striatum [96, 97]. 
Recovery of function and induced sprouting of dopaminergic fibers have been 
demonstrated after implantation of GDNF-releasing microspheres in the striatum of 
parkinsonian rats [98] [99].  
For GDNF delivery in the brain different methods are used to supply the cells 
with growth factor in the brain region, the striatum. This drug-delivery method will not 
result in a natural reconstruction of the nigro-striatal pathway and does not allow a 
more complete functional recovery. 
 
FGF-2 belongs to the fibroblast growth factor family with at least 25 family 
members. Human FGF-2 encodes for a 146 amino acid mature protein with a 17 
amino acid heparin binding site. It is an extensively studied mitogenic growth factor 
known to induce proliferation of neural precursors in embryonic hippocampal culture 
[21]. Research in studying the delivery of FGF-2 to the brain is mainly done using 
viral infected cells [100, 101]. Thereby, King and colleagues could show an increase 
in cell division in vivo [100]. So far, no studies have been done using other strategies 
such as polymer drug delivery for a FGF-2 release in animal models of Parkinson’s 
disease.  
 
To summarize, the polymer based delivery of GDNF is of great importance 
due to long-term release of factors locally at the site of implantation and compared to 
viral transduction it is a safer method. So far, studies only focused on GDNF delivery 
to the striatum without replacing lost dopaminergic cells in the substantia nigra. 
Combining both strategies of cell replacement in the substantia nigra and factor 
delivery spatially and temporally to the brain using polymers could show promising 
results for the restoration of the nigrostriatal pathway. Moreover, polymers could give 
structural support to cells transplanted in the substantia nigra and promote axo-
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dendritic outgrowth towards the striatum. This could be an alternative strategy for the 
treatment of PD.  
 
1.3 The extracellular matrix  
 
1.3.1 Composition of the extracellular matrix 
The extracellular part of tissues is filled by a complex network of macromolecules 
generating the extracellular matrix (ECM). The ECM consists of two main classes of 
macromolecules, which have both structural and adhesive functions: (1) Fibrous 
proteins, such as collagen, fibronectin, laminin and elastin, and (2) 
glycosaminoglycans (GAGs), which are polysaccharide chains and usually linked 
covently to proteins forming proteoglycans. Proteoglycan form a highly hydrated, gel-
like matrix in which the fibrous proteins are embedded. Gels of polysaccharides resist 
compressive forces on the ECM, while collagen fibers provide strength and elastin 
resilience. The relative amount of the different types of matrix macromolecules and 
the way in which they are organized differ depending on the functional requirements 
of the particular tissue. Components of the ECM are produced intracellularly and 
secreted locally by the cells itself and are assembled into a complex structural and 
functional network in close association to the surface of the cell. Once thought that 
ECM serves mainly as a relatively inert scaffold stabilizing the physical structure of 
the tissue, today its known that ECM has a more complex role in native tissue, such 
as providing support and anchorage for cells as well as regulating intracellular 
signaling and dynamic behavior of the cells. Cell adhesion to ECM proteins is 
mediated by integrins, a class of cell surface proteins. These receptors anchor the 
cells to the ECM and also induce intracellular signaling events regulating cell survival, 
development, migration, proliferation, differentiation, survival, shape and function of 
the cells.  
 
Collagen is the most abundant protein in mammals constituting 25% of the 
total protein mass in these animals and accounts for 90% of bone matrix protein 
content. A collagen α chain is about 1000 amino acids long and composed of a 
series of triplet Gly-Pro-X or Gly-X-Hyp sequences with glycine as every third amino 
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acid. As the smallest amino acid with no side chain glycine allows tight packing of 
three left-handed α chains to form a right-handed superhelix where the chains are 
hydrogen-bonded to each other. Proline and hydroxyproline stabilize the helical 
conformation in each α chain with its ring structure and form a helix spontaneously 
without any intrachain hydrogen bonding, where X can be any other amino acid. After 
the procollagen is secreted from the cell by exocytosis, propeptides are removed by 
specific proteolytic enzymes and tropocollagen is formed. Multiple tropocollagen 
molecules spontaneously assemble to larger collagen aggregates such as fibrils via 
covalent cross-links between hydroxylysine and lysine. Further, fibrilar bundles 
aggregate to collagen fibers. The tensile strength of fibrils is dependent on the cross-
linking degree and varies from tissue to tissue. So far, 28 types of collagen have 
been identified and described at which collagen I is with over 90 % the most common 
type.  
 
Fibronectin is a glycoprotein of the ECM consisting of two subunits, each of 
approximately 250 kDa linked by a pair of disulfide bonds. Despite being transcribed 
from the same gene, the monomers are not identical due to alternative splicing of its 
pre-mRNA leading to different isoforms. The monomers itself exhibit multiple 
functional and protein-binding domains each with specific binding sites for other 
matrix macromolecules as well as for the cell surface receptors called integrins. The 
existence of these domains in the fibronectin molecule affects the organization of the 
matrix as well as the cell attachment. The small tripeptide sequence Arg-Gly-Asp or 
RGD binds to the cell receptors integrin and mediates cell binding. Even the 
synthetically produced, short peptide containing the RGD sequence can compete 
with fibronectin for the cell binding site and can be coupled to solid surfaces. As an 
extracellular matrix protein fibronectin is secreted from the cells in soluble form 
initially. At the cell surface fibronectin monomers bind to integrins resulting in a 
stretching of the fibronectin molecule. With a partially unfolding of the protein and an 
unmasking of cryptic fibronectin binding-sites other fibronectin molecules can easily 
associate and form the insoluble fibronectin matrix.  
 
Laminin is a glycoprotein and predominately found in the basal lamina, one of 
the layers of the basement membranes. These are thin sheets of extracellular matrix 
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that underlie epithelial and endothelial cells and surround muscle cells, Schwann 
cells and fat cells. The cross- or T-shaped heterotrimers of laminin consist of one α, 
one ß and one γ chain which are held together by disulfide bonds. So far, five α, 
three ß and three γ chains have been identified in vertebrates. On the globular 
domains of the three shorter arms of the peptide other laminin molecules can bind 
and assemble to sheets independently and are associated with type IV collagen 
networks. The longer arm containing the intersected ß and γ chain helps to anchor 
cells through the integrin receptors to the membrane. The laminin heterotrimers are 
assembled inside the cell, secreted and processed by proteolytic enzymes before 
reaching their final form.  
 
Heparin belongs to the glycosaminoglycans, which are unbranched 
polysaccharids composed of repeated disaccharide units. More precisely, the 
repeating disaccharide units consist of glucoronic or iduronic acid linked to N-
acetylglucosamine or N-acetylgalactosamine, which in most cases is sulfated. 
Because of the highly sulfation of most of their disaccharides, heparin has the 
highest negative charge density of any known biological molecule [102]. Therefore, 
heparin is important for the coupling of growth factors [103, 104]. 
 
For three-dimensional cell migration during physiologic and pathophysiologic 
processes, such as morphogenesis and regeneration as well as tumor invasion and 
metastasis cells developed strategies to pass the ECM. Therefore, the secretion of 
enzymes with proteolytic activity degrading the ECM is one possible option. Among 
others, matrix metalloproteinases (MMPs) are a widely studied calcium-dependent 
and zinc-containing family of endopeptidases participating in ECM degradation. To 
date, 24 different MMPs have been identified in vertebrates [105, 106]. They are 
secreted as inactive pro-MMPs and require an activation process before they 
developed their proteolytic activity [107]. Tissue inhibitors of matrix 
metalloproteinases (TIMPs) are also secreted proteins regulating the activity of 
MMPs [108]. The balance between MMPs and TIMPs regulates ECM degradation 
[109]. MMPs are expressed during development and adulthood in the CNS and are 
known for promoting CNS disease [110].  
 
Introduction 
___________________________________________________________________________ 
___________________________________________________________________ 
 
- 21 - 
1.3.2  Occurrence in the central nervous system  
For a long time, the existence of the ECM in the brain had been discussed 
controversially. It is now clear, that the extracellular space accounting for nearly 20 % 
of the adult brain is composed of many types of extracellular matrix molecules. In the 
central nervous system the ECM is responsible for the regulation of several 
processes both during development and throughout adulthood. Collagen as the 
major component of the ECM in the periphery is only rarely prevalent in the mature 
nervous system. Marginally it is found in the connective tissue associated with the 
nervous system, the basement membrane between the nervous system, and other 
tissues and the sensory end organs [111]. In humans collagen I and collagen II is 
present in the meninges, which is a system of membranes protecting the CNS [112, 
113]. The glycoprotein fibronectin is associated with active morphogenesis, cell 
migration and inflammation, and is expressed in a diverse set of cells in vitro [114, 
115]. It is also found in the developing cortex, especially in neurons migrating into 
specific cortical domains and is thought to support cell division and determine cell 
fate [116]. Punctated laminin expression in various regions has been described 
suggesting a possible role in axon guidance and neuron migration [117]. Beside an 
expression of laminin in the ependymal layer of the spinal cord it is also found along 
the growing fiber tracts [118-120]. During brain development and throughout 
adulthood laminin is expressed in different patterns, such as somatic or sheath form 
as well as small or large punctiform, each in conjunction with different stages of 
neuronal development [121].  
 
1.3.3  Role of ECM in cellular processes 
Cell growth, differentiation and migration are affected by signals from the ECM in 
vitro and in vivo [122-124]. Disrupted cell-matrix interactions are critical for the 
development of the CNS and can cause severe developmental defects [122]. ECM 
influences the proliferation and differentiation of murine neuroepithelial cells and 
neural stem and progenitor cells in vitro [125, 126] as well as the neuronal 
differentiation of postnatal neural stem/progenitor cells in a three-dimensional 
collagen-hyaluronan matrix [127]. The migration of mouse cerebellar neural precursor 
cells in vitro is also affected by ECM molecule [123]. Recently, the effects of several 
ECM components on the survival, proliferation, migration and process extensions of 
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rat oligodendrocyte progenitor cells have been reported [128]. Furthermore, laminin 
as a key ECM molecule enhance neural progenitor generation, expansion and 
differentiation into neurons from human embryonic stem cells [129].  
 
1.4  Tissue engineering strategies for Parkinson’s disease 
 
1.4.1 Properties of an ideal biomaterial scaffold promoting protection, repair 
and regeneration in the brain  
In the last years biomaterials were developed to restore the structure and function of 
damaged or dysfunctional tissue both in cell-based and in non-cellular therapies and 
play central roles in modern strategies in regenerative medicine and tissue 
engineering. In tissue engineering a principle task for biomaterial scaffolds is the 
regulation of cell behavior and tissue progression. For an application in Parkinson’s 
disease several issues has to be considered in the design of an ideal biomaterial 
scaffold (Figure 2) [130].  
 
 
 
Figure 2: Properties of an ideal biomaterial scaffold for applications in Parkinson’s 
disease. An ideal biomaterial scaffold has to fulfill several requirements to restore the 
structure and the function of the damaged tissue in the brain (modified from [130]).  
 
These materials should be non-toxic to the brain tissue and chemically and 
mechanically stable long enough to perform its biological function by supporting 
structurally the surrounding tissue and promoting local neurite and axonal outgrowth. 
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After successful repair or regeneration of the tissue the material should ideally 
degrade without any toxic residues remaining. To prevent inflammatory response or 
cellular reaction biomaterials should be biocompatible with low immunogenicity. 
Moreover, for cell replacement of the lost cell type in PD the biomaterial should serve 
as cell delivery vehicle with various requirements. Ideally it provides controllable 
release of growth factors or bioactive compounds spatially and temporally at the side 
of implantation. Finally, it should serve as three-dimensional extracellular 
microenvironment mimicking all the topographical, mechanical and biochemical cues 
of natural extracellular matrix (EMC). Thus, the biomaterials can promote cell 
adhesion, viability and proliferation as well as provide axon guidance cues for neurite 
extension. 
 
1.4.2 Mimicry of the extracellular matrix as guideline for bioscaffold design 
While the currently applied scaffold materials are mostly based on one main 
structural component [131-134], natural ECM consists of a variety of complex 
supramolecular assemblies of various proteins, proteoglycans and 
glycosaminoglycans [135]. Although the ECM serves as storage system for several 
morphogens in most of the currently applied bioscaffols these molecules are still 
missing. To support effectively cellular multistep processes, engineered matrices 
have to mimic these characteristics more closely. Recently, more advanced materials 
were designed comprising multiple sets of ECM components [136-139] and releasing 
signaling molecules sequentially [140, 141]. Besides combining biomolecules of the 
ECM with scaffold materials enabling cell attachment and morphogen release, the 
strong impact of mechanical properties of ECM on cellular processes were shown 
recently [142]. Accordingly, the defined and systematic variation of the biomolecular 
complexity and the mechanical characteristics of biofunctional matrices are expected 
to open new options for cell replacement therapies. Moreover, engineered 
biodegradable scaffolds could be used to promote and guide axonal outgrowth from 
the transplanted tissue within the mesencephalon into the striatum and thus 
reconstruct the nigro-striatal pathway.  
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1.4.3  starPEG-heparin hydrogels as cell-based and drug delivery system 
Hydrogels received much attention due to their use in a variety of tissue engineering 
applications. They are characterized by a three-dimensional network of hydrophilic 
polymers and thus are able to retain huge amounts of water without destructing their 
polymer network. In the swollen state of hydrogels the polymer content is typically 
below 10 % of weight, whereas 90 % of the remaining mass is water. This high water 
content is similar to natural soft tissue and, hence, exhibit enhanced biocompatibility. 
Moreover, it facilitates the exchange of oxygen, nutrients and waste which is often 
critical for supporting long-term cell/tissue viability in tissue regeneration. On the 
other hand, the high water content in hydrogels may not prevent cytotoxic molecules, 
including cytokines and reactive oxygen species, to penetrate into the hydrogel and 
triggering apoptotic pathways.  
 
A wide range of synthetic and naturally derived materials forming hydrogels 
has been developed for the use in tissue engineering strategies. Naturally derived 
polymers including agarose, alginate, chitosan, collagen, fibrin, gelatin and 
hyaluronic acid have frequently been used because of similarly macromolecular 
properties to natural ECM [131]. They can provide abundant biological signals, such 
as for cell adhesion, and degrade into physiological harmless compounds. On the 
other hand, the can provoke inflammatory and immunological reactions. The 
combination of naturally derived materials with polysaccharide molecules, such as 
hyaluronic acid and heparin has been widely used [143-147]. The glycosaminoglycan 
heparin with its high anionic character is used due to its affinity to many signaling 
molecules. Binding of growth factors such as FGF-2 and GDNF to heparin mainly 
occurs though electrostatic interactions between the negatively charged N- and O-
sulfated groups of heparin to lysine and arginine residues of FGF-2 and GDNF [148, 
149]. Growth factors are characterized by a rapid degradation upon direct 
administration. Binding of FGF-2 and GDNF to heparin leads to a protection of their 
bioactivities against proteolytic modifications [149, 150].  
Besides natural polymers, synthetic hydrogels exhibit great potential for cell 
replacement therapies due to their controllable chemistry and properties enabling a 
defined and systematic variation of mechanical characteristics and biomolecular 
functionalization [151]. Furthermore, synthetic hydrogels minimize the risk for 
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immune response. Among other synthetic polymers, poly (ethylene glycol) (PEG) 
based hydrogels have been extensively used as cell and drug delivery vehicles for 
promoting tissue regeneration [131, 152, 153] since they offer a high biocompatibility 
[154]. Moreover, the polymer is characterized by a hydrophilic and uncharged nature 
and the possibility to easily modify its terminal end groups [133]. Recently, a 
biohybrid hydrogel based on covalently cross-linked heparin and star-shaped 
poly(ethylene glycol) (starPEG) has been developed [155]. Three-dimensional 
networks were formed by cross-linking of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide/N-hydroxysulfo-succinimid (EDC/s-NHS)-activated 
carboxylic acid groups of heparin with amino end-functionalized starPEG. Network 
characteristics and biomolecular functionalization can be gradually and 
independently tuned. Cross-linked heparin molecules within the three-dimensional 
system were subsequently functionalized through covalent attachment of the cell 
adhesion mediating peptide RGD and non-covalent binding of growth factors (Figure 
3). The implantation of the biohybrid hydrogel in the brain proved its feasibility, 
stability and biocompatibility [155].  
 
 
 
Figure 3: Design of EDC/s-NHS activated heparin cross-linked with amino end-
functionalized starPEG to form a non-cleavable biohybrid hydrogel. Additionally, the 
three-dimensional network system can be functionalized with the cell adhesion ligand RGD 
and soluble signaling molecules like growth factors [155]. 
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Furthermore, starPEG-heparin hydrogels were shown to be an efficient FGF-2 
storage and delivery system with adjustable release characteristics decoupled from 
the network structure [156]. Furthermore, for this hydrogel system the independent 
delivery of two growth factors simultaneously has been demonstrated [157]. This 
affinity-based heparin binding delivery system utilizes a non-covalent interaction of 
growth factors with the scaffold providing a controlled protein release. Thus, any 
protein that binds to heparin can be delivered. Many other methods of drug delivery 
have been developed for nerve tissue engineering [158].   
As three-dimensional cell migration through the ECM needs cell adhesion 
[159] as well as proteolytic degradation [160] events, these molecular signals has to 
be displayed by synthetic materials. Matrix metalloproteiases (MMPs) has been 
identified to play a key role in cell invasion and tissue remodeling [161, 162]. So far, 
24 different MMPs have been identified in vertebrates, of which 23 exist in humans 
[106]. They are secreted as pro-MMP (zymogen) and needs to be activated before 
they are able to cleave the ECM [107]. Tissue inhibitors of metalloproteinase (TIMP) 
regulate the MMP activity, and thus the balance between both proteins controls the 
degradation of the ECM [108, 163].  
Oligopeptide substances for MMPs were cross-linked with multiarm end-
functionalized PEG macromers to a three dimensional network [164]. Proteolytic cell 
invasion into these networks has been demonstrated by primary human fibroblasts 
[165]. Recently, a modular biohybrid hydrogel could be formed consisting of heparin 
and peptide-conjugated starPEG cross-linked by MMP sensitive peptides [166] 
(Figure 4). Biomodifications of enzymatically degradable starPEG-heparin hydrogels 
with the cell adhesion mediating ligand RGD and a growth factor support the three-
dimensional migration of human endothelial cells [167]. The protease sensitivity in 
the PEG hydrogels makes this system interesting for an application in PD.  
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Figure 4: Design of EDC/s-NHS activated heparin cross-linked with amino end-
functionalized peptide-conjugated starPEG to form a cleavable biohybrid hydrogel. 
Additionally, the three-dimensional network system can be functionalized with the cell 
adhesion ligand RGD and soluble signaling molecules like growth factors (modified by [168]). 
 
1.5 Aim of the study 
Neurotransplantation in PD is often hampered by a low cell survival and the lacking 
integration of the grafted cells into the nigro-striatal neuronal circuitries due to the 
ectopic transplantation of cells into the striatum. To overcome these problems the 
transplantation of cells orthotopically into their natural position within the Substantia 
nigra could be an alternative approach in PD. For reconstructing the central 
dopaminergic nigro-striatal pathway a biomaterial could be implanted as artificial 
nerve pathway in a so called “bridging” technology to promote dopaminergic 
outgrowth from the Substantia nigra and to re-innervate the striatum. The aim of the 
thesis was to provide the scientific basis for the use of injectable bioscaffolds 
containing chemo attractants modulating cell survival, differentiation and axo-
dendritic outgrowth of dopaminergic cells. Bridging the distance between Substantia 
nigra and striatum with a biomaterial promoting axo-dendritic outgrowth of grafted 
dopaminergic neurons would provide a new regeneration approach in PD.  
 
Hence, the first step of this work was to elucidate the influence of several ECM 
substrates and the cell adhesion mediating peptide RGD on the axo-dendritic 
outgrowth of dopaminergic cells derived from primary fetal mesencephalic cells. For a 
more precise analysis of the dopaminergic cell morphology three different cell 
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characteristics have been investigated including primary branching, total branching 
and neurite elongation. The second element addressed the interaction of primary 
fetal mesencephalic cells and fetal mesencephalic NSCs with the newly developed 
starPEG-heparin hydrogel. The gel system can be modulated in its chemical/physical 
and biomolecular composition and thus is adjustable to a wide range of applications. 
The effects of several hydrogel settings including various material stiffness and 
biomolecular functionalization on the survival of both cellular sources were explored. 
Later, main focus concentrated on primary fetal mesencephalic cells and their 
interaction with hydrogels applicable for an injection into the brain. This included cell 
culture studies with soft hydrogels and their additional modifications with a growth 
factor relevant in terms of PD. Thereby, survival studies, especially of various cell 
types were relevant.  
 
Within the third part of this work the ability of hydrogels serving as an efficient 
storage and delivery system for growth factors were investigated. Analyses consist of 
the separate as well as simultaneous immobilization and release of two distinct 
growth factors. The last part of the work addressed the question whether primary 
fetal mesencephalic cells show the ability to degrade starPEG-heparin hydrogels 
containing proteolytically cleavable peptide linkers. Thereby, the expression of 
MMPs, ECM degrading proteinases was analyzed. Penetration of cells into the 
cleavable hydrogel was determined in comparison to non-cleavable hydrogel to proof 
their biodegradability by primary midbrain cells.  
 
The results of this work could be beneficial to improve cell survival after neural 
transplantation and to facilitate three-dimensional cell growth with the use of a 
cleavable hydrogel being an ideal bioscaffold for an artificial nerve pathway. This 
could be a promising approach for the treatment of PD using the “bridging” 
transplantation technology.  
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2.  Material and Methods 
 
2.1 Material 
2.1.1 Instruments 
Instrument Designation Company 
Balance  SBA 52 Scaltec (Göttingen, Germany) 
Cell incubator  Hera Cell 150 Heidolph (Düsseldorf, Germany) 
Cell Prep Instruments  various VWR  (Darmstadt, Germany) 
Centrifuge, small  Mini Spin Plus Eppendorf (Hamburg, Germany) 
Centrifuge, middle Biofuge Heraeus (Berlin, Germany) 
Clean bench  Hera Safe Heraeus (Berlin, Germany) 
Confocal microscope  SP5 Leica Microsystems (Braunschweig, 
Germany) 
Dissection microscope  Zeiss (Oberkochen, Germany) 
Fluorescence microscope  DM IRE2 Leica Microsystems (Braunschweig, 
Germany) 
Immobilization chamber  customer-made 
PCR cycler  MX 3000 P Stratagene (La Jolla, USA) 
Spin coater module RC5 Suess Microtec (Garching, Germany) 
Thermomixer Comfort Eppendorf (Hamburg, Germany) 
Vortexer  L 46 GLW (Würzburg, Germany) 
Water bath  SW 22 Julabo (Seelbach, Germany) 
 
2.1.2  Chemicals and Consumables 
 
Substance or Consumable Company 
3-Aminopropyltriethoxysilane Sigma-Aldrich (St.Louis, USA) 
Ammonium hydroxide Acros Organics (Geel, Belgium) 
BSA Serva (Heidelberg) 
Collagen I Vitrogen (Palo Alto, USA) 
Cyclo(Arg-Gly-Asp-D-Tyr-Lys)  
(cyclic RGD) 
Peptides International (Louisville, USA) 
Material and Methods 
___________________________________________________________________________ 
___________________________________________________________________ 
 
- 30 - 
1-Ethyl-3-(3-dimethylamino-
propyl)carbodiimide hydrobromide (EDC) 
Sigma-Aldrich (St. Louis, USA) 
Ethanol Roth (Karlsruhe) 
Fibronectin Roche (Basel, Switzerland) 
Glucose Sigma-Aldrich (St. Louis, USA) 
Heparin (for collagen/heparin) Sigma-Aldrich (St. Louis, USA) 
Heparin (MW 14,000 – for starPEG) Merck (Darmstadt, Germany) 
Hydrochloric acid Merck (Darmstadt, Germany) 
Hydrogen peroxide Merck (Darmstadt, Germany) 
Immuno 96 MicroWell™ Solid Plates 
(MaxiSorp™) 
Thermo Fisher Scientific (Rochester, USA) 
Isopropanol Merck (Darmstadt, Germany) 
Laminin Roche (Basel, Switzerland) 
2-mercaptoethanol Sigma-Aldrich (St. Louis, USA) 
N-hydroxysulfosuccinimide (s-NHS) Sigma-Aldrich (St. Louis, USA) 
Paraformaldehyde (PFA) Sigma-Aldrich (St. Louis, USA) 
Poly-D-lysine Sigma-Aldrich (St. Louis, USA) 
Sodium bicarbonate Sigma-Aldrich (St. Louis, USA) 
Sodium carbonate Merck (Darmstadt, Germany) 
Poly(ethylene glycol) (starPEG) (MW 
10,000) 
Polymer Source (Dorva, Canada) 
Poly(ethylene glycol) (starPEG) (MW 
15,200) 
Polymer Source (Dorva, Canada) 
Poly(octadecene-alt-maleic anhydride) 
(POMA) 
Polysciences Inc. (Warrington, USA) 
Triton-X 100 Thermo Fisher Scientific (Rockford, USA) 
 
2.1.3  Solutions and Buffers 
 
Substance or consumable Company 
Accustain Sigma-Aldrich (St. Louis, USA) 
Donkey serum Jackson Immunoresearch (West Grove, 
USA) 
HBSS Gibco (Invitrogen, Carlsbad, USA) 
Hoechst 33342 Molecular Probes (Invitrogen, Carlsbad, 
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USA) 
Hepes buffer Sigma-Aldrich (St. Louis, USA) 
PBS Gibco (Invitrogen, Carlsbad, USA) 
Propidium iodide (PI) Molecular Probes (Invitrogen, Carlsbad, 
USA) 
RNAlater® Ambion® (Austin, USA) 
Sigmacote Sigma-Aldrich (St. Louis, USA) 
TBST wash buffer Dako (Glostrup, Denmark) 
Ultra Pure (PCR-) Water Roth (Karlsruhe, Germany) 
Vectashield Vector (Burlingame, USA) 
 
2.1.4  Kits 
 
Kit Company 
Brilliant ® SYBR®
 
Green QRT-PCR Master 
Mix  
Stratagene (La Jolla, USA) 
RNeasy ®
 
Mini  Qiagen (Hilden, Germany) 
RNeasy ® Lipid Tissue Mini Kit  Qiagen (Hilden, Germany) 
Human FGF basic Quantikine ELISA Kit R&D Systems (Minneapolis, USA) 
GDNF Emax® Immuno Assay System Promega (Madison, USA) 
 
2.1.5  Enzymes, Growth factors and Antibodies 
Enzymes 
Enzymes Company 
DNase (RNA isolation) Qiagen (Hilden, Germany) 
DNase (cell preparation – fetal primary 
mesencephalic cells) 
Roche (Grenzach-Wyhlen, Germany) 
DNase (cell preparation – fetal 
mesencephalic neural stem cells) 
Sigma-Aldrich (St. Louis, USA) 
Trypsin Gibco (Invitrogen, Carlsbad, USA) 
 
 
Material and Methods 
___________________________________________________________________________ 
___________________________________________________________________ 
 
- 32 - 
Growth factors 
Growth factors Company 
EGF (human, recombinant) Sigma-Aldrich (St. Louis, USA) 
GDNF (human, recombinant) Sigma-Aldrich (St. Louis, USA) 
FGF-2 (human, recombinant) Sigma-Aldrich (St. Louis, USA) 
Forskolin (human, recombinant) Sigma-Aldrich (St. Louis, USA) 
IL-1b (Interleukin-1) (human, recombinant)  Sigma-Aldrich (St. Louis, USA) 
 
Antibodies 
Primary Antibodies 
Antibody Dilution Company 
Mouse anti-microtubuli-associated protein 2 
(MAP2) 
1:500 BD Biosciences (Franklin, USA) 
Mouse anti-ß-Tubulin III (Tuj1) 1:500 Millipore (Billerica, USA) 
Rabbit anti-tyrosine hydroxylase (TH) 1:500 PelFreeze (Rogers, USA) 
Rabbit anti-Nestin 1:500 Abcam (Cambridge, UK) 
Rabbit anti-Olig2 1:500 Chemicon (Temecula, Canada) 
Rabbit anti-Glial Fibrillary Acidic Protein 
(GFAP) 
1:1000 Millipore (Billerica, USA) 
Rabbit anti-matrix metalloproteinase-2 
(MMP-2) 
1:100 Abcam (Cambridge, UK) 
Rabbit anti- matrix metalloproteinase-9 
(MMP-9) 
1:100 Abcam (Cambridge, UK) 
Sheep anti-tyrosine hydroxylase (TH) 1:500 PelFreeze (Rogers, USA) 
 
Secondary Antibodies 
Antibody  Company 
Alexa Fluor® 488-conjugated donkey anti-
mouse 
1:500 Invitrogen (Carlsbad, USA) 
Alexa Fluor® 488-conjugated donkey anti-
sheep 
1:500 Invitrogen (Carlsbad, USA) 
Alexa Fluor® 594-conjugated donkey anti-
mouse 
1:500 Invitrogen (Carlsbad, USA) 
Alexa Fluor® 594-conjugated donkey anti-
rabbit 
1:500 Invitrogen (Carlsbad, USA) 
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CF633 phalloidin conjugate 1:40 Biotium (Hayward, USA) 
 
 
2.1.6  qRT-PCR Primers 
 
Primer Quiagen (Hilden, Germany)  (not specified by manufacturer) 
MMP-2 QuantiTect®Primer Assay Mm_MMP2_1_SG 
MMP-9 QuantiTect®Primer Assay Mm_MMP9_1_SG 
 
 
2.1.7 Cell Culture Media 
 
Expansion medium for fetal mesencephalic neural stem cells (NSCs) 
Medium component Company 
65% (v/v) DMEM   
((+)4.5g/l Glucose, (+) L-Glutamine, (+) Pyruvat) 
Gibco (Tulsa, UK) 
32% (v/v) F-12+GlutaMAX™ ((-) L-Glutamine) Gibco (Tulsa, UK) 
2 % B-27 Supplement Gibco (Tulsa, UK) 
100 IU/ml Penicillin Gibco (Tulsa, UK) 
0.1 mg/ml Streptomycin Gibco (Tulsa, UK) 
20 ng/µl EGF Sigma-Aldrich (St. Louis, USA) 
20 ng/µl FGF-2 Sigma-Aldrich (St. Louis, USA) 
 
Differentiation media for fetal mesencephalic neural stem cels (NSCs) 
Medium component Company 
65% (v/v) DMEM   
((+)4.5g/l Glucose, (+) L-Glutamine, (+) Pyruvat) 
Gibco (Tulsa, UK) 
32% (v/v) F-12+GlutaMAX™  
((-) L-Glutamine) 
Gibco (Tulsa, UK) 
2 % B-27 Supplement Gibco (Tulsa, UK) 
100 IU/ml Penicillin Gibco (Tulsa, UK) 
0.1 mg/ml Streptomycin Gibco (Tulsa, UK) 
5 µM Forskolin (human, recombinant) Sigma-Aldrich (St. Louis, USA) 
100 pg/ml IL-1b (Interleukin-1) (human, recombinant) Sigma-Aldrich (St. Louis, USA) 
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Basic-Medium for primary fetal mesencephalic cells 
Medium component Company 
87% (v/v) DMEM  
((+)4.5g/l Glucose, (+) L-Glutamine, (-) Pyruvat) 
Gibco (Tulsa, UK) 
10% (v/v) FCS Sigma-Aldrich (St. Louis, USA) 
10 mM Hepes buffer Gibco (Tulsa, UK) 
8 mM Glucose Sigma-Aldrich (St. Louis, USA) 
100 IU/ml Penicillin Gibco (Tulsa, UK) 
0.1 mg/ml Streptomycin Gibco (Tulsa, UK) 
 
 
2.1.8  Animals 
Male and female wild-type C57Bl6 (25-35 g) were purchased from Charles River, 
Sulzfeld. They were housed, bred and treated according to the guidelines of the 
European Community (86/609/EEC) and the Society for Neuroscience (January 
1985). All experiments were approved by the local ethical committee. Timed pregnant 
females were obtained by overnight mating. The day of detection of the vaginal plug 
was considered as E1. 
 
 
2.2  Methods 
 
2.2.1  Preparation of hydrophobic glass coverslips 
The surface of the glass cover slips to be siliconized must be clean and dry. Cover 
glasses in a Petridish with enough Sigmacote solution for 15 sec and remove the 
solution afterwards. The silicone solution forms a covalent thin film on the glass 
surface which is water repellent. Allow the treated glass surface to air dry in a hood. 
After the heptane has evaporated, the siliconized glasses can be oven dried at 100 
°C for 30 min. Rinse the siliconized glass cover slips with MilliQ water to remove the 
HCl by-products before use.  
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2.2.2  Preparation of aminosilanized glass cover slips 
1) Pre-cleaning 
To remove particles from the glass surface cover slips were immersed in MilliQ water 
in a Teflon shelf, incubated for 30 min in MilliQ water in an ultrasonic water bath and 
rinsed 2-3x in MilliQ water. To further pre-clean the glass cover slips were incubated 
in Ethanol in an ultrasonic water bath and rinsed 2-3x in MilliQ water subsequently.  
 
2) RCA-Cleaning 
Cover slips were immersed in a Teflon shelf with pre-heated (70 °C) RCA solution 
(volume ratio of MilliQ water : H2O2 : NH3 = 5 : 1 : 1)  for 10 min and rinsed 2-3x in 
MilliQ water subsequently. After cleaning the glass cover slips should be further 
processed immediately because fast re-contamination processes occurring at 
environmental conditions. 
 
3) Aminosilanization 
Cover slips were placed in isopropanol : MilliQ water (9 : 1) solution containing 20mM 
3-aminopropyltriethoxysilane in a Teflon shelf for 2 h. After rinsing samples in 
isopropanol thoroughly the glass surface were dried with N2 gas and placed in a 
drying oven at 120 °C for 1 h. Because of attacking the amino groups by oxidation 
the drying step and subsequent gel formation should be carried out in a shortly after 
aminosilanization. 
 
2.2.3  Covalent protein immobilization of ECM components and poly-D-lysine 
on surface modified glass cover slips 
In a first step a thin film of 0.16 % poly(octadecen-alt-maleic anhydride) (POMA) 
solution in THF were spin coated at 4000 rpm for 30 s on the surface of freshly 
prepared aminolisanized glass cover slips by using a spin coater module. For a 
stable covalent binding of polymers to the SiO2 surface of glass cover slips samples 
were placed at 120 °C for 2 h in an oven, where imide bonds with the aminosilane of 
the pre-coated cover slips were generated. Later, glass cover slips were flushed in 
acetone for 15 min and were dried with N2 gas immediately. Before proteins of the 
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ECM were covalently immobilized to the modified glass surface, cover slips were 
autoclaved at 120 °C for 20 min and subsequently oven dried at 120 °C for 2 h.  
Collagen fibrils were reconstituted according to the manufacturer’s manual and 
diluted further as follows: collagen I : 10 x PBS : 0.1 M NaOH = 8 : 1 : 1. Components 
were mixed and kept on ice. By adding ice cold PBS the appropriate concentration 
was adjusted. The collagen solution was placed on the modified glass surface and 
formation of fibrils was initiated by incubation for 1 h at 37 °C.    
For tropocollagen I coating acidic collagen I solution were incubated on 
modified glass surface overnight.  
For preparation of collagen I / heparin coatings non ice cold fibrillar collagen I 
solution were mixed with in PBS diluted heparin. The mixture were incubated for 15 
min on ice and placed on modified glass surfaces. For the formation of fibrils the 
cover slips were incubated for 1 h at 37 °C.  
Laminin were diluted according to the manufacturer’s manual and 
concentration were adjusted by adding an appropriate volume of DMEM ((+)4.5g/l 
Glucose, (+) L-Glutamine, (-) Pyruvat). After placing the laminin solution on glass 
surface the cover slips were incubated for 1 h at 37 °C.  
In PBS diluted fibronectin were placed on modified glass surface and 
incubated for 1 h at room temperature. 
RGD dissolved in borate buffer (pH 8) were placed on modified glass surface 
and incubated for 2 h at room temperature. 
After appropriate incubation the cover slips were washed 3 times with PBS. 
Following concentrations were used: collagen I (1.2 mg/ml), tropocollagen I (0.1 
mg/ml), collagen I / heparin (1.2/0.4 mg/ml), laminin (0.01 mg/ml), fibronectin (0.05 
mg/ml), RGD (0.2 mg/ml) and poly-D-lysine (0.05 mg/ml). 
 
2.2.4  Preparation of functionalized starPEG-heparin hydrogels 
For covalent binding of starPEG with heparin an activation of heparin carboxylic acid 
groups by EDC and s-NHS is necessary prior combining both matrix components. To 
obtain surface immobilized networks the starPEG-heparin hydrogel solution were 
placed on freshly amino end-functionalized glass cover slips. The activated 
carboxylic acid groups of heparin attach covalently and anchor the hydrogel to the 
modified glass surface. In order to spread the gel solution equally on the glass slide 
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the gel solution was covered with a hydrophobic glass cover slip. After polymerization 
of the hydrogel the hydrophobic cover slip was removed.  
 
Preparation of non-cleavable starPEG-heparin hydrogel networks 
By cross-linking amino end-functionalized four-arm starPEG with EDC/s-NHS-
activated carboxylic acid groups of heparin the starPEG-heparin hydrogels were 
formed. For this total polymer content of 11.6% and a molar ratio of EDC and s-NHS 
of 2 : 1 were used. To generate gels with different physical and chemical 
characteristics the molar ratio of starPEG (MW 10,000) to heparin (γ=2, γ=4, γ=6) 
was varied. First, starPEG and heparin were each dissolved in one third of the total 
volume of ice-cold MilliQ water by ultrasonication and stored on ice. After EDC and s-
NHS were dissolved in one sixth of the total volume in ice-cold MilliQ water the 
solution were added to heparin, mixed and incubated for 15 min on ice. After heparin 
carboxylic acid groups were activated the starPEG solution were added and mixed 
for 15 min at 8 °C and 900 rpm. Subsequently, 3.11 µl of the gel mixture were placed 
on aminosilanized glass cover slips to allow covalent attachment of heparin through 
its activated carboxylic acid groups. In order to spread the gel solution equally on the 
glass slide the gel solution was covered with a hydrophobic glass cover slip. After 
polymerization of the hydrogel over night at 22 °C the hydrophobic cover slip was 
removed and hydrogels were washed five times with PBS to remove any remaining, 
non-bound matrix components. After intensive washing the gels were stored for 24 h 
in PBS to initialize gel swelling. For cell culture the swollen gels were sterilized using 
UV-treatment for 30 min.   
 
Biomodification of non-cleavable starPEG-heparin hydrogels 
PBS-swollen gels were washed three times for 10 min in 1/15 mM phosphate buffer 
(pH = 5) at 4 °C. For activation of the carboxylic acid groups of heparin and a 
subsequent biomodification with cyclo (Arg-Gly-Asp-D-Tyr-Lys) (RGD) a solution of 
50 mM EDC and 25 mM s-NHS in 1/15 mM phosphate buffer were added and gels 
were incubated for 45 min at 4 °C. Afterwards, the gels were washed 3 times in 100 
mM borate buffer (pH = 8, 4 °C) to remove excessive EDC/s-NHS and immediately 
immersed in 250 µl RGD-solution (50µg/ml in 100 mM borate buffer) to finally reach 
an amount of 15 µg RGD bound to the network. After incubation for 2h at room 
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temperature the samples were washed 3 times in PBS for 1 min. For immobilization 
of growth factors (FGF-2 and/or GDNF) to the heparin hydrogel the particular protein 
were dissolved in PBS at the desired concentration of 1 µg/ml. Swollen pure or RGD 
modified gels were immersed in 200µl/cm2 FGF-2 and/or GDNF solution at room 
temperature for 6 h followed by a washing in PBS twice.  
 
Preparation of cleavable starPEG-heparin hydrogel networks 
The generation of biodegradable gels was performed as described for the non-
cleavable gels using starPEG-MMP conjugates with a molecular weight of PEG of 
15,200 Da. Especially, amide conjugated MMP-cleavable peptides with the cleavable 
sequence GPQG↑↓IWGQ were used. Biodegradable gels were functionalized with 
cyclic RGD with a final amount of 4 or 32 µg.  
 
2.2.5  Isolation and cultivation of primary fetal mesencephalic cells  
Time-pregnant females at embryonic day 14 (E14) were killed according to National 
Institutes of Health guidelines and with approval of the local animal care committee. 
Primary fetal cells were isolated from the mesencephalic tegmentum using a 
dissection microscope. After removing the meninges carefully the tissue samples 
were cut with a scalpel into small pieces and incubated with 2 ml 0.5% 
Trypsin/EDTA, 3ml HBSS and 200 µg/ml DNAse for 7min at 37 °C. Samples were 
centrifuged for 2 min at 500 x g and the supernatant was removed. For dissociation 
of cells 3 ml pre-warmed Basic medium and 200 µg/ml DNAse were added and 
samples were homogenized to a quasi single cell suspension by mechanical 
trituration using a fire polished Pasteur pipette. After 10 min of incubation the 
supernatant containing the dissociated cells were removed. Existing cell pellets were 
re-suspended with 3 ml pre-warmed Basic medium and 200 µg/ml DNAse and cells 
were dissociated by mechanical trituration up to three times. Dissociated cells were 
seeded with a density of 2,500 cells/mm2 to pre-coated cover slips or starPEG-
heparin hydrogels. The complete medium was changed on the 3rd day in vitro (DIV) 
and on the 5th DIV. Primary fetal mesencephalic cells were cultured at 37 °C in a 
humidified atmosphere of 5% CO2 and 95% air (21% O2).  
All incubation steps were performed at room temperature if not mentioned else 
wise. 
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2.2.6  Isolation, expansion and differentiation of fetal mesencephalic neural 
stem cells 
Mesencephalic NSCs were dissected from mice at E14 as described above. After 
removal of the meninges the tissue samples were cut into small pieces with a scalpel, 
incubated in 0.1 % trypsin for 5 min, triturated and centrifuged for 4 min at 500 x g. 
The supernatant was removed, 40 mg/ml DNase was added and the sample was 
homogenized to a quasi single cell suspension by mechanical trituration using a fire 
polished Pasteur pipette. After incubation for 10 min at 37 °C the cell suspension 
were centrifuged for 4 min at 500 x g, the supernatant was discarded and cells were 
re-suspended in 8 ml pre-warmed expansion medium containing 20 ng/ml EGF and 
FGF-2. NSCs were expanded as suspension cultures in so-called “neurospheres” in 
25 cm2 flasks for one week at 37 °C in a humidified atmosphere of lowered oxygen 
conditions 5% CO2, 92% N2 and 3%O2 and growth factors (20 ng/ml EGF and FGF-
2) were added twice a week. After 2 – 3 days in culture fetal neurosphere formation 
was observed.  
To induce differentiation cells were transferred into a falcon tube and 
centrifuged for 4 min at 500 x g to remove the supernatant. After that, they were 
washed once by resuspension in 5 ml PBS followed by another centrifugation step for 
4 min at 500 x g before 8 ml pre-warmed differentiation media containing 5 mM 
forskolin and 100 pg/ml interleukin (IL)-1b were added. Cells were transferred to pre-
coated cover slips or starPEG-heparin hydrogels.  
All steps were performed at room temperature if not mentioned else wise. 
 
2.2.7  Immuncytochemistry 
After 7DIV cells were washed once with PBS and subsequently fixed for 30 sec with 
Accustain solution. After rinsing three times with PBS cells were blocked against 
unspecific antibody labeling using blocking solution (3% donkey serum in PBS 
containing 0,2% TritonX-100) for 1.5 h. Primary antibodies diluted in blocking solution 
were added to the cells and incubated overnight at 4 °C. Subsequently, cells were 
rinsed three times with PBS for 10 min and incubated with the respective fluorophore-
labeled secondary antibodies for 1 h in the dark. Afterwards cells were rinsed four 
times with PBS for 10 min and cell nuclei were counterstained with Hoechst 33342 
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(7,5 ng/ml) for 3 min. After washing cells three times with PBS cover slips were 
removed from the culture dish and mounted on microscopy slides using Vectashield.  
 
For immunostaing of MMPs cells were once washed with PBS after 7 DIV, 
fixed for 15 min with 4% PFA on ice and subsequently rinsed three times with PBS. 
After blocking with 1% BSA (in PBST - containing 0.025% Triton) for 30 min, primary 
antibodies were added and cells were incubated overnight at 4 °C. Subsequently, 
cells were rinsed three times with PBS and incubated with the respective fluorophore-
labeled secondary antibodies for 1 h in the dark followed by washing with PBS four 
times for 10 min. Counterstaining of the cell nuclei were performed as described 
above.  
 
For phalloidin staining cells were washed once with PBS after 1 DIV or 5 DIV, 
fixed for 15 min with 4% PFA on ice and rinsed three times with PBS. To 
permeabilize the cell membrane 0.5% TritonX-100 was added and cells were 
incubated for 10 min followed by three times washing step with PBS. To block non-
specific binding 3% BSA were added. After 30 min cells were washed once with PBS, 
the 633 conjugated phalloidin antibody in 1 % BSA were added and cells were 
incubated for 1 h in the dark. Cells were washed three times with PBS and cell nuclei 
were stained like mentioned above.  
All incubation steps were performed at room temperature if not mentioned else 
wise. 
 
2.2.8  Cell survival studies 
Cell survival was analyzed by propidium iodide (PI) nucleic acid staining. PI is a 
fluorescent molecule and intercalates to DNA. Once the dye is bound to nucleic acid, 
its fluorescence is enhanced 20- to 30-fold, the fluorescence excitation maximum is 
shifted to 535 nm and the fluorescence emission maximum to 617nm. While the 
membrane of viable cells is impermeable for PI, the dye can penetrate cell 
membranes of dying or dead cells. This method is commonly used for identifying 
dead cells.  
After 7DIV the cell culture medium was removed, cells were washed once with 
PBS and a solution containing 325 µl PBS, 125 µl cell culture medium, 80 ng/ml PI 
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and 4 ng/ml Hoechst 33342 were added to each sample. Cells were incubated with 
the intercalating agents for 6 min at 37 °C and subsequently the fluorescence was 
measured. 
 
2.2.9  Isolation of RNA 
Isolation of RNA from adherent cells 
Adherent cells were detached from their culture dish using a cell scraper after 7 DIV 
on different substrates. The cell solution was transferred in a falcon tube and 
centrifuged for 4 min at 316 x g. After removal of the supernatant the cell pellet was 
re-suspended with PBS. The cell solution was centrifuged once again for 1 min at 
316 x g and the cell pellet were re-suspended in 350 µl RLT lysis buffer containing 1 
% 2-mercaptoethanol. Isolation of RNA from cells was performed with the RNeasy® 
Mini Kit followed by elution with RNase-free DNase according to the manufacturer’s 
manual. In this procedure, RNA is bound to a silica gel membrane and washed 
several times to remove contaminants and enzyme inhibitors before elution. 
 
Isolation of RNA from tissue 
Tissue from brain regions of interest were placed in 500 µl RNAlaterTM solution. After 
transferring samples into 500µl of Quizol-lysis-buffer the tissue was homogenized. 
Isolation of RNA from cells was performed with the RNeasy Mini Kit followed by 
elution with RNase-free DNase according to the manufacturer’s manual. In this 
procedure, RNA is bound to a silica gel membrane and washed several times to 
remove contaminants and enzyme inhibitors before elution. 
 
2.2.10 Quantitative real-time reverse transcription PCR (qRT-PCR) 
Quantitative real-time reverse transcription PCR (qRT-PCR) is a powerful tool for 
gene expression analyses. By the combination of real time PCR with reverse 
transcription messenger RNA and non-coding RNA in cells and tissue can be 
amplified and simultaneously quantified. 
QRT-PCR was performed using Brilliant® SYBR® Green QRT-PCR Master 
Mix Kit according to the manufacturer’s manual. The fluorophore SYBR® Green bind 
to all double-stranded DNA (dsDNA) molecules regardless of sequence and enhance 
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the fluorescence emission due to a conformational change in the dye. During 
denaturation, all DNA becomes single-stranded. At this stage, SYBR Green is free in 
solution and produces little fluorescence. The fluorescence signal is measured at the 
end of each elongation phase and allows the user to monitor the linear accumulation 
of PCR products in real-time over a range of PCR cycles. Thus, the increase in the 
SYBR® Green signal correlates with the amount of product amplified during PCR. 
The results can be displayed as an amplification plot, which reflects the change in 
fluorescence during cycling. Based on a threshold cycle (Ct) the initial copy number 
can be quantitated during real-time PCR analysis. Ct is defined as the cycle at which 
fluorescence is determined to be statistically significant above background. This 
value was used for the gene expression analysis. Since SYBR® Green binds to any 
dsDNA it cannot discriminate between specific products, non-specific products and 
primer-dimers. Since all double-stranded PCR products will contribute to the signal 
intensity the assay also included a melting curve analysis of the qRT-PCR products 
demonstrating product specificity after amplification.  
 
For the qRT-PCR analysis 1 μl (approximately 200 ng) of total RNA was 
transcribed to cDNA by reverse transcription and subsequently amplified using 0.5 
μM of both sense and antisense primer. Product specificity was demonstrated by 
melting curve analysis of qRT-PCR products. All experimental steps were performed 
on ice. The following pipetting scheme was used for qRT-PCR representative for one 
reaction: 
 
Component Volume 
SYBR® Green Master Mix 12,5 µl 
reverse transcriptase mix 1 µl 
primer mix (forward and reverse) 2 µl 
H2O 8,5 µl 
RNA (or H2O as control) 1 µl 
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The following cycling protocol was used: 
 
Cycles Duration Temperature Procedure 
1 25 min 50 °C First-strand cDNA synthesis 
1 15 min 95 °C  initial denaturation of cDNA / activation of DNA 
polymerase 
35 15 sec 
20 sec 
30 sec 
95 °C 
60 °C 
72 °C 
denaturation of DNA 
binding of primers to DNA 
elongation of primers to synthesise complementary 
strand / measurement of fluorescence intensity 
1 1 min 95 °C denaturation of PCR products / melting curve 
analysis 
1 30 sec 55 °C annealing of PCR products to generate dissociation 
curves 
 
The results were expressed relative to the housekeeping gene Hmbs 
(hydroxymethylbilane synthase), whose expression did not vary under the 
experimental conditions used. Quantification of relative RNA levels were performed 
using following formula of the comparative threshold cycle (∆∆Ct
 
method): 
 
2^ (Ct
 
(housekeeping gene) – Ct
 
(target gene)) 
 
2.2.11 Enzyme-linked immunosorbent assay 
Enzyme-linked immunosorbent assay (ELISA) is a sensitive and specific enzyme 
immunoassay technique for the quantitative analysis of molecules including 
cytokines, chemokines, growth factors, proteases and more in an antibody sandwich 
format. To bind soluble factors a capture antibody is coated to a microplate. The 
analyte is bound to a detection antibody conjugated to horseradish peroxidase. 
Several washing steps remove unbound material. By adding a chromogenic 
substrate solution the color develops in proportion to the amount of analyte present in 
the sample. Subsequently the color development is stopped and absorbance is 
measured at 450nm. 
Immobilization and release studies of proteins by surface-bound starPEG-
heparin hydrogels were performed in custom-made incubation chambers that allowed 
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only minimal interaction of the protein solution with areas not originating from the 
hydrogel. 200 µl of FGF-2 and/or GDNF (0.5 or 1 µg/ml) solution were added per 
cm2. After immobilization over night at 22 °C the protein solution was taken out 
followed by washing with PBS twice. Afterwards the proteins were allowed to release 
from the gels into 250 ml/cm2 of Basic medium containing 10 % FCS or Basic 
medium without FCS, respectively. Samples taken at intervals were stored at -80 °C 
until be analyzed by ELISA. An equal volume of fresh medium was added back at 
each time point. Each of these solutions was collected and assayed in triplicates 
using an ELISA Quantikine kit for FGF-2 or Emax® ImmunoAssay System for GDNF 
according to the manufacturer’s manual. Immunoassays for the quantitative analysis 
of FGF-2 were performed using pre-coated microplates delivered by the assay 
company. Within the enzyme immunoassay for the detection of GDNF non-coated 
Nunc-ImmunoTM MaxiSorpTM plates with a high affinity to molecules with mixed 
hydrophilic/hydrophobic domains had to be coated prior usage.    
All incubation steps were performed at room temperature if not mentioned else 
wise.  
 
2.2.12 Cell counting and neurite length quantification 
Cells were analyzed by conventional fluorescence microscopy and images were 
acquired using Leica FW4000. Image analysis, quantification of total cell 
number/positive cells and analysis of the axo-dendritic outgrowth of dopaminergic 
cells were performed with ImageJ 1.37v (developed by W. Rasband, National 
Institutes of Health, Bethesda, USA) or PhotoshopCS2 (Adobe). For the 
quantification of positive cells at least five coverslips were counted per time point and 
condition. Analysis of the axo-dendritic outgrowth was carried out on images showing 
the full extent of neurite outgrowth and on single DA neurons without any cell-cell 
contacts to other DA neurons. The number of neurites extending directly from the cell 
soma of dopaminergic cells was defined as primary neurites and quantified. At least 
10 cells per time point and condition were analyzed.  
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2.2.13 Statistics 
Statistical significance was computed using Student’s t-test or one-way ANOVA and 
post-hoc t-test with Bonferoni adjustment using the SPSS software version 18.0 
(SPSS Institute, Chicago, USA). All data are presented as mean ± S.E.M. (standard 
error of the mean). P-values < 0.05 were considered as significant. 
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3.  Results 
 
3.1  Extracellular matrix molecules influence growth properties of 
primary fetal mesencephalic cells 
As components of the ECM influence several cellular processes in vitro and in vivo, 
the development of biomaterials mimicking regulatory characteristics of natural ECM 
their effects on the growth properties of primary fetal mesencephalic cells has to be 
investigated. Proteins of the ECM were covalently immobilized to POMA modified 
glass surfaces and growth properties of primary fetal mesencephalic cells isolated at 
E14 were analyzed after 5 days in vitro (DIV) using bright field microscopy and after 7 
DIV with immunofluorescence staining for dopaminergic cells using fluorescence 
microscopy. Fetal cells were seeded in a density of 2,500 cells per mm2 on ECM-
coated glass surfaces and immunofluorescence staining observing DAergic cells was 
performed against tyrosine hydroxylase (TH), an enzyme catalyzing the conversion of 
L-tyrosine to L-DOPA the precursor of dopamine (Figure 5). Influences of ECM 
molecules on axo-dendritic outgrowth of DAergic cells were monitored including 
analysis of effects on (1) the number of neurites extending directly from cell soma 
(primary neurites) indicating a primary branching capability, (2) the number of all 
neurites indicating a branching capability of a complete neuron, and (3) the length of 
neurite extension suggesting a possible role in promoting neurite elongation. All 
quantifications were carried out using the Image J plug-in Neuron J and were 
compared to growth properties on glass surfaces coated with poly-D-lysine (PDL), a 
widely used coating agent in vitro. With its polycationic property, PDL encourage the 
interaction with anionic sites on cells promoting their attachment.  
Although a lot of cells adhere to coated glass surfaces, survive and form cell 
extensions, differences in growth properties of fetal primary mesencephalic cells 
cultured on various ECM components were detected at representative bright field 
images after 5 DIV (Figure 5A). A homogenously cell spreading was achieved on 
collagen I-, fibronectin- and PDL-coated glass surfaces, whereas a formation of cell 
clusters was observed when cells were cultured on glass surfaces coated with 
tropocollagen I, collagen I/heparin, laminin and RGD.  
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Figure 5: Influence of extracellular matrix molecules on growth properties of primary 
fetal mesencephalic cells.  
Cells were isolated, seeded at a density of 2,500 cells per mm2 and cultured for a period of 7 
days on various ECM components. (A) Representative bright field images after 5 DIV shows 
different growth properties of primary fetal mesencephalic cells cultured on ECM molecules. 
Scale bar 200 µm.  (B-D) After 7 DIV cells were immunostained for TH, axo-dendritic 
outgrowth of DAergic neurons compared to PDL was observed with fluorescence microscopy 
and quantified using Image J. Data are expressed as mean ± S.E.M. * - P<0.05, ** - P<0.01, 
*** - P<0.005, ANOVA; n=3-4. TC – tropocollagen I, C – collagen I, CH – collagen I/heparin, 
LM – laminin, FN – fibronectin, RGD - Arg-Gly-Asp PDL – poly-D-lysine. 
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In Figures 5B – D, influences of ECM molecules on axo-dendritic outgrowth of 
DAergic cells are displayed. A significant increase in the amount of primary neurites 
of DAergic cells in respect to PDL (100%) with 111±3% (F-value 0.897, P<0.01; 
ANOVA; n=4) were observed when cell were cultured on tropocollagen I. No effects 
of several other ECM components on the amount of primary neurites of DAergic cells 
in respect to PDL were observed possessing similar quantities of primary neurites 
(P>0.05; ANOVA; n=3-4). 
No effect on branching of DAergic cells in respect to PDL was achieved when 
cell were cultured on different ECM molecules (F-value 1.664, P>0.05, ANOVA; n=3-
4) (Figure 5C). 
Fibronectin and RGD stimulate the neurite extension of dopaminergic cells 
significantly with an increase in neurite length of 42% (142±14%; F-value 3.856, 
P<0.05, ANOVA; n=4) and 69% (169±10%; F-value 3.856, P<0.005, ANOVA; n=3) 
compared to PDL substrate, respectively. Other ECM molecule, such as 
tropocollagen I, collagen I , collagen I/heparin and laminin showed now neurite 
promoting activity compared to PDL (P>0.05, ANOVA; n=4) (Figure 5D). 
Taken together, Figure 5 demonstrates the different growth properties of 
primary fetal mesencephalic DAergic neurons cultured on ECM modified glass 
surfaces. ECM components influence cell morphology of primary fetal mesencephalic 
DAergic cells and it seems that fibronectin and its cell binding sequence RGD can 
promote axo-dendritic outgrowth of DAergic cells.  
 
3.2  Evaluation of the starPEG-heparin hydrogel 
.  
3.2.1 Physical/chemical properties of starPEG-heparin hydrogels  
Hydrogels with differing molecular ratios of starPEG and heparin can be synthesized. 
By varying the amount of 4-arm starPEG and constant heparin content, different 
hydrogels with various network characteristics can be generated. Increasing the 
starPEG/heparin content will generate hydrogels with a more cross-linked polymer 
network [155]. An increase in the number of cross-links result in a denser network 
with higher rigidity (higher storage modulus) and a restricted water uptake (lower 
swelling) [155]. In cooperation with the research group of Prof. Carsten Werner at the 
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Leibniz Institute of Polymer Research Dresden hydrogels with different 
physical/chemical characteristics and molecular ratios of starPEG/heparin from γ=2, 
γ=4 and γ=6 with different cross-linking degrees, material rigidity and swelling 
degrees were synthesized in this work. Thereby, γ=2 indicates starPEG-heparin 
hydrogels with low cross-linking degrees, low storage moduli and high swelling 
properties, whereas γ=6 hydrogels possess much higher cross-linking and storage 
moduli with lower swelling degrees. Hydrogels with γ=4 show intermediate network 
characteristics. 
 
3.2.2 Biofunctionalization of starPEG-heparin hydrogels  
While physical characteristics of the hydrogel can be changed the heparin content 
remains constant. To tune the cell-adhesive properties of the hydrogel the cell 
adhesion mediating peptide RGD were covalently attached to the hydrogel. Covalent 
bonds were formed between EDC/s-NHS activated carboxylic acid groups of heparin 
and amino groups of lysine on the RGD. As the heparin content remain constant 
independent from network characteristic, the RGD amount were found to be similar 
[155].  Furthermore, due to the anionic character of heparin and its affinity for many 
soluble factors, growth factors can be incorporated independent from cross-linking 
degree through non-covalent interactions with heparin. Growth factors known to 
stimulate cellular processes can be bound to the hydrogel to further functionalize the 
hydrogel platform. Thus, the hydrogels display a modular system in which network 
characteristics can be gradually varied, while keeping the heparin content and the 
biomolecular functionalization constant [155]. As RGD was shown to promote neurite 
elongation of DAergic cells, this peptide was covalently bound to activated carboxyl 
groups of the heparin molecule within a starPEG-heparin hydrogel. Furthermore, 
growth factors, such as FGF-2 and GDNF were incorporated to the hydrogel system. 
 
3.2.3 StarPEG-heparin hydrogels function as an efficient storage and delivery 
system for FGF-2 and GDNF 
Since large amounts of heparin with high anionic charge density are bound to 
hydrogels, numerous growth factors can be incorporated and stabilized by this 
molecule. But not only storage of cellular effectors also their constant and 
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independent delivery by hydrogels is important for biomedical applications. 
Therefore, the analysis of immobilization and release of growth factors known to be 
important in treatment of PD are crucial. FGF-2 with its cell survival promoting activity 
and GDNF known to increase dopaminergic cell survival and to stimulate axo-
dendritic outgrowth were immobilized to star-PEG heparin hydrogels. Either single 
protein solution with 1 µg/ml protein or incubation solutions with a combination of 
both factors (0.5 µg/ml or 1 µg/ml each) based on the concentrations used for in vitro 
studies. Protein immobilization and release were performed in custom-made 
immobilization chambers minimizing protein interaction with surfaces of the device. 
Besides analyzing whether the hydrogel can be used as an efficient storage and 
delivery system for various amounts of growth factors, the evidence that uptake and 
release of GDNF occur independently from cross-linking degree of the hydrogel were 
submitted. In general, the release was carried out in the same cell culture media as 
used for in vitro studies of primary fetal mesencephalic cells if not indicated elsewise. 
The amount of protein was quantified by enzyme-linked immunosorbent assays 
(ELISA). 
 
To investigate the uptake and release of growth factors from hydrogels either 
1 µg/ml FGF-2 and 1µg/ml GDNF as single components or 0.5 µg/ml and 1 µg/ml as 
factor combinations were immobilized to gels with low cross-linking degree, γ=2 
(Figure 6).  
Figure 6A shows the immobilization of similar quantities for both proteins either 
as single factors or as factor combinations. For single factors 256±1 ng/scaffold for 
FGF-2 and 258±1 ng/scaffold for GDNF (P>0.05, Student’s t-test; n=3) could be 
immobilized from a solution of 1 µg/ml protein. Similar amounts of growth factors 
immobilized from a solution containing both proteins in a concentration of 1 µg/ml 
each were found (FGF-2: 257±1 ng/scaffold; GDNF: 260±2 ng/scaffold) (P>0.05, 
Student’s t-test; n=3) indicating that the two factors do not affect each other while 
interacting with the hydrogel matrix. Moreover, the same protein amount was 
immobilized either as single factor or as factor combination (FGF-2 single: 256± 1 
ng/scaffold and in combination 257±1 ng/scaffold (P>0.05, Student’s t-test; n=3)) 
(GDNF single: 258±1 ng/scaffold and in combination 260±2 ng/scaffold (P>0.05, 
Student’s t-test; n=3)). Furthermore, a linear correlation between the concentration of 
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incubation solution and the amount of immobilized protein were observed. When a 
solution of 0.5 µg/ml of both proteins were incubated with the hydrogel 120±2 
ng/scaffold FGF-2 and 130±1 ng/scaffold GDNF were immobilized (P<0.005, 
Student’s t-test; n=3). Notably, the amount of immobilized FGF-2 when 0.5 µg/ml was 
used is more than twice lower compared to the protein amount when 1 µg/ml FGF-2 
is loaded. For GDNF the amount of immobilized protein is almost twice higher when 
the incubation solution exhibits a twice higher concentration. 
Subsequently, the diffusion-based release of FGF-2 and GDNF from 
hydrogels was studied. Figures 6B and C illustrate the cumulative release of FGF-2 
alone or in combination with GDNF over a period of 7 days. An initial burst release 
was observed within the first 24 hours followed by a continuous, slow release over 
time. Regardless, whether factors were immobilized alone or in combination the 
released protein amount were similar. For an immobilization with 1 µg/ml FGF-2 53±1 
ng/scaffold and 50±3 ng/scaffold of released protein were observed for single or 
combined FGF-2, respectively after 168 h (P>0.05, Student’s t-test, n=3) (Figure 6B 
left). For GDNF a overall protein amount of 47±2 ng/scaffold for single factor and 
37±6 ng/scaffold for the combination were analyzed (P>0.05, Student’s t-test, n=3), 
whereas half of the protein amount is released, when only half of the quantity is 
immobilized (FGF-2/0.5 µg/ml: 30±4 ng/scaffold; GDNF/0.5 µg/ml: 19±2 ng/scaffold; 
P>0.05, Student’s t-test, n=3) (Figure 6B right). Furthermore, a linear correlation 
between the amount of protein used for immobilization and the quantities being 
released were investigated for factor combinations (FGF2: 30±4 ng/scaffold for 0.5 
µg/ml and 50±3 ng/scaffold for 1µg/ml; GDNF: 19±2 ng/scaffold for 0.5 µg/ml and 
37±6 ng/scaffold for 1.0 µg/ml). 
For an immobilization of 1 µg/ml FGF-2 as single factor or in combination huge 
protein amounts were released within the first 24 hours (FGF-2 single: 20±0.2% and 
in combination: 18±1% (P>0.05, Student’s t-test; n=3); GDNF single: 17±1% and in 
combination: 14±2% (P>0.05, Student’s t-test; n=3). After 7 days the amount of 
released protein is only slightly increased (FGF-2 single: 21±0.2% and in 
combination: 20±1% (P>0.05, Student’s t-test; n=3); GDNF single: 18±1% and in 
combination: 15±2% (P>0.05, Student’s t-test; n=3) indicating that huge quantities of 
growth factors still remain in the hydrogel matrix.  
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In summary, the use of star-PEG-heparin hydrogels as efficient storage and 
delivery system were demonstrated. Furthermore, the independent loading and 
release of two different factors in two different concentrations could be demonstrated.  
 
 
Figure 6: Uptake and release of FGF-2 and GDNF separately or in combination with 
each other.  
Hydrogels were immobilized with single FGF-2 or GDNF or combinations of both. The protein 
amount was quantified after several time points using ELISA. (A) The amount of 
electrostatically bound FGF-2 and/or GDNF per scaffold is shown. (B-C) The plots display 
the cumulative amount of bound protein released by the hydrogels and the cumulative 
percentage of released protein, respectively for duration of 7 days. Dashed lines indicate the 
release in case of factor combinations, whereas continuous lines denote the release in case 
of single factors. Data are expressed as mean ± S.E.M. *** - P<0.005; Student’s t-test, n=3. 
 
     
Results 
___________________________________________________________________________ 
___________________________________________________________________ 
 
- 53 - 
Recently, it was shown that the release of FGF-2 is different when using 
medium free of serum proteins compared to medium with bovine serum albumine 
(BSA). Roughly 10 % more FGF-2 could be obtained in serum conditions compared 
to medium without BSA. Therefore, investigating the release of GDNF is of quite big 
importance due to the use of serum-free medium to culture NSCs. In detail, 1 µg/ml 
GDNF were immobilized to gels with low cross-linking degree (γ=2) and the release 
were either performed in serum media containing 10 % FCS used for primary fetal 
mesencephalic culture or in serum-free media used for fetal mesencephalic NSC 
culture (Figure 7).  
In both conditions an initial burst release was shown and the release slowly 
continued over the period of time (Figure 7A). As expected, the overall release of 
GDNF in serum containing medium was found to be much higher than the release in 
serum-free medium (serum-containing medium: 47±2 ng/scaffold; serum-free 
medium: 4.3±0.3 ng/scaffold; P<0.005, Student’s t-test, n=3). Roughly 10 % less 
GDNF under SFM condition were quantified compared to SM settings (serum-
containing: 18±1 %; serum-free medium: 1.6± 0.1%; P<0.005, Student’s t-test, n=3) 
(Figure 7B).  
 
 
 
Figure 7: Uptake and release of GDNF in dependence on the release medium. 
Hydrogels were immobilized with 1 µg/ml GDNF and protein was released into serum-free 
(SFM) or serum containing medium (SM) with 10 % FCS. The protein amount was quantified 
at several time points using ELISA. (A-B) Plots show the cumulative protein amount per 
scaffold and the cumulative percentage of released protein, respectively. Data are expressed 
as mean ± S.E.M., Student’s t-test, n=3.  
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3.2.4 Fetal mesencephalic neural stem cells respond to mechanical and 
biomolecular properties of starPEG-heparin hydrogels  
Fetal mesencephalic NSCs are promising cell source for neural transplantation in PD. 
To investigate their survival and differentiation properties on different settings of 
hydrogels, cells were isolated at E14 and expanded as suspension cultures for one 
week prior use. Cells were transferred to differentiation media with 5 mM forskolin 
and 100 pg/ml interleukin (IL)-1β and seeded on hydrogels. Three different biohybrid 
gels with an increasing molecular ratio of star-PEG to heparin from γ=2, γ=4 and γ=6 
were used to form hydrogels with different cross-linking degrees, storage moduli and 
swelling properties. Each hydrogel with defined cross-linking degree were used 
without biomolecular functionalization and with covalent attachment of cell adhesion 
peptide RGD and FGF-2. Both factors were tested alone or in combination. Thus, the 
influence of network characteristics and biomolecular functionalization on fetal 
mesencephalic NSCs could be investigated. 
Figure 8 displays the interaction of NSCs with hydrogels of various network 
characteristics and biomolecular functionalizations in a two-dimensional cell culture 
after 5 DIV. NSCs grew even on unmodified hydrogels with the best cell survival 
obtained on hydrogels with the highest stiffness. Regardless of biomolecular 
functionalization, the hydrogel with the highest cross-linking degree showed highest 
cell survival. Biomolecular functionalization with RGD and FGF-2 or the combination 
of both had very different effects on NSCs. Cells cultured on plain gels and on FGF-2 
loaded gels showed a “neurosphere”-like aggregates with no speading of cells 
outside of the “neurosphere”. On FGF-2 loaded hydrogels “neurospheres” appeared 
much larger indicating a higher cell survival. Attachment of integrin binding ligand 
RGD led cells spread on hydrogels without “neurosphere”-like formation. For 
hydrogels with RGD and FGF-2 loading a tremendous increase of cell survival were 
observed.  
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Figure 8: Interaction of various starPEG-heparin hydrogels and fetal mesencephalic 
neural stem cells (NSCs).  
Cells were isolated, expanded in suspension culture for 7 days, transferred to differentiation 
media and seeded on hydrogels. Representative bright field images show the different 
growth properties of fetal mesencephalic NSCs after 5 DIV. Scale bar, 200 µm. 
 
 
To investigate the differentiation behavior of NSCs cultured on various gel 
types, cells were stained for the neural stem cell marker Nestin as well as for Tuj1, 
which is expressed in immature neurons and their committed progenitors. Cell nuclei 
were counterstained with Hoechst 33342, a DNA intercalating agent. Figure 9 shows 
representative immunofluorescence images on low cross-linked hydrogels (γ=2). 
Similar results were found on more cross-linked hydrogels (γ=4, γ=6). NSCs on plain 
hydrogels showed only poor differentiation, whereas incorporation of the cell 
adhesion mediating peptide RGD led to differentiation of NSCs into neurons. Nearly a 
homogenously Nestin staining were observed in “neurosphere”-like formations on 
FGF-2 loaded gels with sporadic neuronal differentiation and higher cell survival. By 
combining RGD peptide and FGF-2 to hydrogels many Nestin+ NSCs and Tuj1+ 
neurons with mature axo-dendritic arborization were investigated with an tremendous 
increase in cell survival.  
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Figure 9: Influence of various hydrogels on survival and differentiation of fetal 
mesencephalic neural stem cells (NSCs).  
Cells were isolated and expanded in suspension culture for 7 days. After transferring into 
differentiation media cells were seeded on hydrogels and cultured for 7 DIV. Representative 
images of the immunoreaction to the neural stem cell marker Nestin and immature nerve cell 
marker Tuj1 on hydrogels with the lowest cross-linking degree (γ=2) are shown. Scale bar, 
200 µm. 
 
 
3.2.5 Network structure and biomolecular functionalization of starPEG-heparin 
hydrogels influence the cell survival and axo-dendritic outgrowth of 
primary fetal mesencephalic cells 
To increase the viability and maturity of cells, the hydrogels were modified with the 
cell adhesion peptide RGD and loaded with the soluble mitogen FGF-2. Additionally, 
the influence of different structural and mechanical characteristics on the interaction 
with primary fetal mesencephalic cells was evaluated. The cells were cultured on a 
set of different biohybrid gels with an increasing molecular ratio of star-PEG to 
heparin from γ=2, γ=4 and γ=6. Each hydrogel with defined cross-linking degree 
were used without biomolecular functionalization and with covalent attachment of cell 
adhesion peptide RGD and FGF-2. Both factors were tested alone or in combination. 
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Thus, the influence of network characteristics and biomolecular functionalization on 
primary fetal mesencephalic cells could be investigated. Primary fetal mesencephalic 
cells were isolated at E14 and seeded with a cell density of 2,500 cells per mm2 on 
biohybrid gels.  
To investigate the influence of hydrogels with various biophysical and 
biomolecular characteristics the 2-dimensional cell culture was monitored using bright 
field microscopy after 5 DIV (Figure 10). Different growth behavior was observed 
depending on cross-linking degree and biomolecular functionalization. Plain gels 
without biomolecular modification showed only low cell survival, whereas the 
attachment of RGD to the hydrogel led to a slight increase in cell survival. With the 
incorporation of FGF-2 the cell survival increased dramatically with exception for the 
hydrogel with the highest cross-linking degree. High survival rates were also obtained 
with combination of covalently attached RGD and heparin-conjugated FGF-2 even for 
the highest cross-linking network structure.  
 
 
 
Figure 10: Interaction of various starPEG-heparin hydrogels and primary fetal 
mesencephalic cells.  
Cells were isolated and seeded at a density of 2,500 cells per mm2. Representative bright 
field images show different growth properties of primary fetal mesencephalic cells after 5 
DIV. Scale bar, 200 µm. 
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In order to study the survival of neuronal cell types after 7 DIV cells were 
stained for the mature neuronal marker MAP2 as well as for TH identifying DAergic 
cells. Cell nuclei were counterstained with Hoechst 33342, a DNA intercalating agent. 
Representative immunofluorescence images in Figure 11 show the immunoreactivity 
to MAP2 and TH on low cross-linked hydrogels (γ=2). Similar result were found for 
more cross-linked hydrogels (γ=4, γ=6). Plain and RGD-modified gels showed only a 
low cell survival with a low number of MAP2+ cells per mm2, whereas on FGF-2-
loaded hydrogels with or without RGD the cell number and the amount of MAP2+ 
cells per mm2 were increased.  
 
 
Figure 11: Interaction of starPEG-heparin hydrogels with neuronal cell types of 
primary fetal mesencephalic cells.  
Cells were isolated and seeded at a density of 2,500 cells per mm2. After 7 DIV cells were 
stained for the mature neuronal marker MAP2 and the marker for dopaminergic cells TH. Cell 
nuclei were counterstained with Hoechst 33342. Representative images of the 
immunoreaction to the mature neuronal marker MAP2 and the marker for dopaminergic cells 
TH on hydrogels with the lowest cross-linking degree (γ=2) are shown. Scale bar, 50 µm. 
 
To determine the cell survival on hydrogels with different chemical/physical 
characteristics (γ=2, γ=4, γ=6) and biomolecular functionalization (pure gel, modified 
with RGD, loaded with FGF-2 or with a combination of RGD+FGF-2) Hoechst+ cells, 
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MAP2+ cells as well as TH+ cells were quantified in respect to mm2 after 7 DIV 
(Figure 12). The number of Hoechst + cells indicates the total cell number.  
Figure 12A displays the quantitative analysis of the total cell number. On 
hydrogels with low network density (γ=2) significant more cells were quantified on 
hydrogels with FGF-2 and RGD+FGF-2 compared to pure and/or RGD modified 
hydrogels with the same network characteristics (FGF-2: 5702±500 cells/mm2 (γ = 2) 
and RGD+FGF-2: 6016±254 cells/mm2 both compared to pure gel 39±7 cells/mm2 
and both compared to RGD 40±8 cells/mm2; F-value 136.243, P<0.005, ANOVA; 
n=3). A similar survival pattern of Hoechst+ cells were achieved on FGF-2 and 
RGD+FGF-2 hydrogels with middle network density (γ=4) compared to pure and/or 
RGD modified hydrogels with the same cross-linking degree (FGF-2: 4086±602 
cells/mm2 and RGD+FGF-2: 6897±372 cells/mm2 both compared to pure gel 30±10 
cells/mm2 and both compared to RGD 192±19 cells/mm2; F-value 136.243, P<0.005, 
ANOVA; n=3). RGD+FGF-2 loaded hydrogels with highest cross-linking degree (γ=6) 
displayed the highest cell survival compared to pure gel and RGD modified hydrogels 
with the same network density (RGD+FGF-2: 7407±254 cells/mm2  compared to pure 
gel 15 ± 9 cells/mm2  and compared to RGD modified gel 137±40 cells/mm2;F-value 
136.243, P<0.005, ANOVA; n=3). Interestingly, only few cells survived on FGF-2 
loaded hydrogels with highest cross-linking degree as also observed in the bright 
field images. The combination of RGD and FGF-2 to this gel type could erase this 
inhibitory effect and a significant increase of cell survival was quantified (RGD+FGF-
2: 7407±254 cells/mm2 compared to FGF-2 (10±5 cells/mm2; F-value 136.243, 
P<0.005, ANOVA; n=3). Furthermore, the low cell survival on FGF-2 loaded 
hydrogels with highest cross-linking degree could be increased when cells were 
cultivated on lower cross-linked gels (FGF-2: 10±5 cells/mm2 (γ=6) compared to 
5702±500 cells/mm2 (γ=2) and compared to 4086±602 cells/mm2 (γ=4); F-value 
136.243, P<0.005, ANOVA; n=3). On other hydrogel settings only low cell survival 
were achieved independent on cross-linking degree or biomolecular functionalization. 
Taken together, a high cell survival could be achieved on hydrogels with heparin-
conjugated FGF-2 except for hydrogels with the highest cross-linking degree. For the 
combination of both factors RGD and FGF-2 high cell survival rates could be 
obtained even for highly cross-linked hydrogels.  
Results 
___________________________________________________________________________ 
___________________________________________________________________ 
 
- 60 - 
Similar results were achieved for MAP2-immunoreactivity of mesencephalic 
cells grown on hydrogels (Figure 12B). Significant more MAP2+ cells were obtained 
on FGF-2 and RGD+FGF-2 loaded hydrogels with middle cross-linking degree when 
compared to pure gels with same network characteristic (FGF-2: 73±10 cells/mm2 
(γ=4), RGD+FGF-2: 76±17 cells/mm2 (γ=4) both compared to pure gel 3±1 cells/mm2 
(γ= 4), F-value 8.972, P<0.05, ANOVA; n=3). Furthermore, a significant increase of 
mature neuronal cells were obtained on hydrogels with highest network density 
compared to pure gel, RGD modified and FGF-2 loaded hydrogels with the same 
cross-linking degree (RGF+FGF-2: 105±30 cells/mm2 (γ=6) compared to pure gel 
2±2 cells/mm2 (γ=6), RGD modified gel 16±6 cells/mm2 (γ=6) and FGF-2 loaded gel 
0.1±0.1 cells/mm2 (γ=6), F-value 8.972, P<0.005, ANOVA; n=3). Hydrogels loaded 
with FGF-2 and middle cross-linking degree also promote the survival of MAP2+ cells 
compared to hydrogel with the same biomolecular functionalization but higher cross-
linking degree (FGF-2: 73±10 cells/mm2 (γ=6) compared to 0.9±0.9 cells/mm2 (γ=6); 
F-value 8.972, P<0.05; ANOVA; n=3). To conclude, hydrogels with RGD+FGF-2 
incorporation and middle and high network density as well as FGF-2 loaded gel with 
middle cross-linking degree were the best conditions for the survival of mature 
neuronal cells obtained so far.  
Figure 12C displays the survival of dopaminergic cells (TH+) on different 
settings of hydrogels. Significant more TH+ cells survive when grown on RGD 
modified hydrogels with low or middle cross-linking degree compared to pure gel with 
the same network characteristic (RGD: 0.3±0.01 (γ=2) compared to pure gel 
0.1±0.05 (γ=2); F-value 11.313, P<0.05, ANOVA; n=3) (RGD: 0.5±0.03 (γ=4) 
compared to pure gel 0.1±0.03 (γ=4); F-value 11.313, P<0.005, ANOVA; n=3). The 
incorporation of FGF-2 or the combination of RGD+FGF-2 to hydrogels with middle 
network density significantly decrease the number of TH+ cells compared to RGD 
modified hydrogel with the same cross-linking degree (FGF-2: 0.2±0.07 (γ=4) and 
RGD+FGF-2: 0.2±0.09 both compared to RGD modified gel; F-value 11.313, P<0.01, 
ANOVA; n=3). But RGD incorporation to hydrogels with high cross-linking degree 
significantly decrease the amount of dopaminergic cells compared to hydrogels with 
the same biomodification but middle network density (RGD: 0.1±0.02 (γ=6) compared 
to 0.5±0.03 (γ=4), F-value 11.313, P<0.005, ANOVA; n=3). In other conditions the 
survival of dopaminergic cells were not affected neither by network characteristic nor 
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by biomolecular functionalization. To summarize, RGD modified hydrogels with 
middle cross-linking degree seems to be a condition, where dopaminergic cells 
survive most.  
 
Figure 12: Interaction of starPEG-heparin hydrogels with neuronal cell types of 
primary fetal mesencephalic cells.  
Cells were isolated and seeded at a density of 2,500 cells per mm2. After 7 DIV cells were 
stained for the mature neuronal marker MAP2 and the marker for dopaminergic cells TH. Cell 
nuclei were counterstained with Hoechst 33342. Quantitative analysis of total cell number, 
MAP2 and TH displays a dramatically increase in total cell number and MAP2+ neuronal cells 
cultured on FGF-2-loaded hydrogels, whereas RGD-modified hydrogels led to higher survival 
of TH+ cells. Data are expressed as mean ± S.E.M. For simplification values are indicated as 
significant within the gel type and strength of significance are shown for P<0.05. # - 
significant compared to pure gel, * - significant compared to RGD modified gel, § - significant 
compared to FGF-2 loaded gel; ANOVA; n=3.  
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Besides investigating the cell survival of primary fetal mesencephalic cells 
cultured on the various hydrogel settings, the influence of these hydrogels on the 
axo-dendritic outgrowth of dopaminergic cells is indispensable for an application in 
vivo. Studying axo-dendritic outgrowth of DAergic neurons were performed similar to 
the analysis on ECM compounds. In detail, primary fetal mesencephalic cells were 
isolated at E14, seeded in a density of 2,500 cells per mm2 on three gel types with 
different cross-linking degrees (γ=2, γ=4, γ=6) with/without functionalization with the 
cell binding ligand RGD and/or the growth factor FGF-2. After 7 DIV cells were 
stained for DAergic cells (TH+ cells) and analysis were performed using a 
fluorescence microscope. For the analysis of axo-dendritic outgrowth of DAergic 
cells, 10 cells per condition were quantified using the Image J plug-in Neuron J. 
Hydrogels with less than 10 dopaminergic cells were indicated as not representative 
and thus excluded from quantification. Results are displayed in Figure 13. In all 
conditions three independent experiments were analyzed (n = 3).  
DAergic cells grown on hydrogels with low and middle network density showed 
independent on their cross-linking degree and biomolecular functionalization similar 
amounts of primary neurites of dopaminergic cells (Figure 13A). As no DAergic cells 
could be quantified on FGF-2 loaded hydrogel with highest cross-linking degree, cells 
on hydrogels with the same biomolecular functionalization but lower cross-linking 
degree were found to be significant compared to stiff hydrogels (FGF-2: 2.5±0.1 
(γ=2) compared to 0.0±0.0 (γ=6), F-value 7.590, P<0.05, ANOVA; n=3; 3.2±0.3 (γ=4) 
compared to 0.0±0.0 (γ=6), F-value 7.590, P<0.005, ANOVA; n=3). Furthermore, on 
hydrogels with highest cross-linking degree a significant increase in branching of the 
primary neurites were obtained for RGD modified gels and hydrogels containing both 
RGD and FGF-2 compared to pure gel and FGF-2 loaded hydrogel due to the less 
survival of DAergic cells under these conditions (RGD: 3.0±0.2 (γ=6) compared to 
pure gel 0.0±0.0 (γ=6) and to FGF-2 0.0±0.0 (γ=6); F-value 7.590, P<0.005, ANOVA; 
n=3; RGD+FGF-2: 2.8±0.2 (γ=6) compared to pure gel 0.0±0.0 (γ=6) and FGF-2 
0.0±0.0 (γ=6); F-value 7.590, P<0.01, ANOVA; n=3). In summary, DAergic neurons 
showed nearly the same capability for primary branching regardless of the cross-
linking degree and biomolecular functionalization with exceptions for the plain 
hydrogel and the FGF-2 incorporated hydrogel with the highest cross-linking degree. 
For these gel types not enough DAergic cells for quantification were available.  
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That hydrogel settings also influence the total branching of DAergic cells is 
displayed in Figure 13B. Significantly higher branching of DAergic cells were 
obtained on FGF-2 loaded hydrogels with middle cross-linking degree compared to 
hydrogels with low and high network density (FGF-2: 12±2 (γ=4), compared to 
4.9±0.3 µm (γ=2); F-value 15.392, P<0.005, ANOVA; n=3 and compared to 0.0±0.0 
(γ=6); F-value 15.392, P<0.005, ANOVA; n=3). Furthermore, dopaminergic cells on 
RGD modified hydrogels with middle network density promoted significantly the 
branching of dopaminergic cells compared hydrogel with low network density (RGD: 
13±1 (γ=4) compared to 5.3±0.4 (γ=2); F-value 15.392, P<0.005, ANOVA; n=3). 
Incorporation of RGD and FGF-2 to hydrogels with middle cross-linking degree led to 
a significant decrease in DAergic branches compared to RGD modification alone 
(RGD+FGF-2: 6.3±1.0 (γ=4) compared to RGD 13±1 (γ=4), F-value 15.392, P<0.05, 
ANOVA; n=3) A significant increase in the total amount of branches of DAergic cells 
were obtained on hydrogels with middle cross-linking degree when RGD or FGF-2 is 
incorporated compared to pure gel with the same network characteristic (RGD: 13± 1 
(γ=4) compared to pure gel 3.5±2.0 (γ=4), F-value 15.392, P<0.005, ANOVA; n=3); 
FGF-2: 12±2 (γ=4) compared to pure gel 3.5±2.0 (γ=4), F-value 15.392, P<0.005, 
ANOVA; n=3). No quantification of neurite branching could be performed on FGF-2 
loaded hydrogel with highest cross-linking degree due to the less cell survival of 
DAergic cells under these conditions. At this cross-linking degree a significant 
increase of the total amount of neurite branches were obtained for RGD modified 
gels and hydrogels containing both RGD and FGF-2 compared to pure gel and FGF-
2 loaded gels (RGD: 11±1 (γ=6) compared to pure gel 0.0±0.0 µm (γ=6) and to FGF-
2 0.0±0.0 (γ=6), F-value 15.392, P<0.005, ANOVA; n=3; RGD+FGF-2: 7.8±1.0 (γ=6) 
compared to pure gel 0.0±0.0 (γ=6) and FGF-2 0.0±0.0 (γ=6); F-value 15.392, 
P<0.005, ANOVA; n=3). In all other conditions the total branching capability of 
DAergic cells were detected to be similar to hydrogels with the same cross-linking 
degree or biomolecular functionalization. Taken together, the strongest effect on the 
branching of dopaminergic cells were obtained when cells were cultured on RGD-
modified and FGF-2 bound hydrogels with intermediate cross-linking degree. 
 
 The neurite length of DAergic cells were also affected by hydrogel 
settings (Figure 13C). A significant increase in the neurite length of dopaminergic 
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cells were obtained on hydrogels with middle cross-linking degree when RGD or 
FGF-2 is incorporated compared to pure gel (RGD: 861±46 µm (γ=4) compared to 
pure gel 162±91 µm (γ=4); F-value 12.227; P<0.01, ANOVA; n=3; FGF-2: 1191±259 
µm (γ=4) compared to pure gel 162±91 µm (γ=4), F-value 12.227, P<0.005, ANOVA; 
n=3). Similar to the analysis of the primary neurites and the total amount of branches 
the neurite length of dopaminergic cells could not be quantified on FGF-2 loaded 
hydrogel with highest cross-linking degree due to their less cell survival under these 
conditions. At this cross-linking degree a significant increase in neurite length were 
obtained for RGD modified gels and hydrogels containing both RGD and FGF-2 
compared to pure gel and FGF-2 loaded gels (RGD: 890±111 µm (γ=6) compared to 
pure gel 0.0±0.0 µm (γ=6) and to FGF-2 0.0±0.0 µm (γ=6); F-value 12.227, P<0.005, 
ANOVA; n=3) (RGD+FGF-2: 754±124 µm (γ=6) compared to pure gel 0.0±0.0 µm 
(γ=6) and FGF-2 0.0±0.0 µm (γ=6), F-value 12.227, P<0.005, ANOVA; n=3). 
Significantly longer neurites were also obtained on FGF-2 loaded hydrogels with 
middle cross-linking degree compared to hydrogels with low and high network density 
(FGF-2: 1191±259 µm (γ=4) compared to 441±13 µm (γ=2) and compared to 0.0±0.0 
µm (γ=6); F-value 12.227, P<0.005, ANOVA; n=3)). In all other conditions 
dopaminergic cells showed similar neurite length to hydrogels with the same cross-
linking degree or biomolecular functionalization. In summary, DAergic neurons 
showed nearly the same neurite length elongation regardless of the cross-linking 
degree and biomolecular functionalization with exceptions for the plain hydrogel and 
the FGF-2 incorporated hydrogel with the highest cross-linking degree. For these gel 
types not enough dopaminergic cells for quantification were available. The most 
promising condition in promoting the neurite length was obtained on hydrogels with 
middle cross-linking degree and FGF-2 incorporation.  
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Figure 13: Influence of various starPEG-heparin hydrogels on axo-dendritic outgrowth 
of primary fetal mesencephalic cells.  
Cells were isolated and seeded at a density of 2,500 cells per mm2. After 7 DIV cells were 
stained for the marker for dopaminergic cells TH, axo-dendritic outgrowth were observed 
using fluorescence microscopy and cells were analyzed via Image J. (A-C) Different 
parameters of axo-dendritic outgrowth were analyzed including number of primary neurites 
extending directly from the cell soma, number of all neurites indicating neuronal branching 
capability and length of neurite extension suggesting a possible role in promoting neurite 
elongation. Data are expressed as mean ± S.E.M. For simplification values are indicated as 
significant within the same gel type and strength of significance are shown for p ≤ 0.05. # - 
significant compared to pure gel, * - significant compared to RGD modified gel, § - significant 
compared to FGF-2 loaded gel.; ANOVA; n=3. 
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3.2.6 Incorporation of FGF-2 and GDNF to starPEG-heparin hydrogels decides 
on survival/proliferation of primary fetal mesencephalic cells 
Since the influence of matrix elasticity and biomolecular functionalization of starPEG-
heparin hydrogels on cellular processes could be demonstrated, the influence of 
other hydrogel-bound growth factors on cell survival and cell fate has to be 
investigated. Cardinally GDNF counts as promising factor for the treatment of PD. 
Therefore, RGD-modified hydrogels were loaded either with GDNF, FGF-2 or with a 
combination of both factors in a concentration of 1 µg/ml for each factor. Studies 
were focused on the influence of soft hydrogels with a low star-PEG heparin ratio 
(γ=2) due their possible use in cell transplantation strategies. Primary fetal 
mesencephalic cells were isolated at E14, seeded with a density of 2,500 cells per 
mm2 on biohybrid gels and were cultured for 7 days.  
Figure 14 displays survival of primary fetal mesencephalic cells on hydrogels 
with lowest cross-linking degree (γ=2). Bright field images show the different cell 
survival on hydrogels with different biomolecular functionalization after 5 DIV (Figure 
14A). Like already investigated, a high cell survival was observed on RGD+FGF-2-
bound hydrogels with nearly a homogenous cell culture. In contrast, on RGD-
modified hydrogels loaded with GDNF cells grew in aggregates and with considerably 
lower cell survival. The combination of both growth factors with RGD-bound gels 
seems to exhibit similar survival rates like for RGD+FGF-2-loaded hydrogels. 
These observations were confirmed by quantitative analysis of Hoechst 
33342+ cells indicating the total cell number per mm2 after 7 DIV (Figure 14C). A 
similar cell survival on FGF-2 loaded hydrogels (5885±112 cells/mm2) and on 
hydrogels with both growth factors (5322±691 cells/mm2; F) were observed. In 
contrast to that, only very few cells were investigated on RGD-modified hydrogels 
loaded with GDNF (183±53 cells/mm2; P<0.005, Student’s t-test; n=3).  
 To identify the amount of dead cells under these conditions after 7 DIV cells 
were stained for PI, a commonly used agent identifying dead cells, and cell nuclei 
were counterstained with Hoechst 33342. Figure 14B shows representative 
fluorescence images of Hoechst/PI staining confirming the observations for cell 
survival rates obtained from bright field images.  
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Figure 14: Survival of primary fetal mesencephalic cells on starPEG-heparin hydrogels 
with different biomolecular functionalizations.  
Cells were isolated and seeded at a density of 2,500 cells per mm2 on hydrogels with 
different modifications. (A) Representative bright field images show different survival of 
primary fetal mesencephalic cells on hydrogels after 5 DIV. (B) Representative fluorescence 
images were observed with staining for Hoechst 33342 and PI after 7 DIV. Scale bar, 100 
µm. (C) The survival of cells was analyzed by quantification of Hoechst+ cells after 7 DIV. (D) 
The percentage of dead cells (PI+) is plotted in respect to culture conditions. Scale bar, 100 
µm. Data are expressed as mean ± S.E.M.  *** - P<0.005, Student’s t-test; n=3.  
 
 
In Figure 14D the quantified number of PI+ cells as percentage to the total cell 
number is plotted with respect to hydrogel modifications. Generally, only low rates (< 
10%) of apoptosis and/or necrosis were observed. No significant differences were 
observed, but highest values were obtained for cells on GDNF-loaded gels, where 
6.2±2.1% of the cells were PI positive. Hydrogels with FGF-2 (1.7±0.3%) and the 
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combination of FGF-2 and GDNF (1.8±0.1%) showed very low cell death (P>0.05, 
Student’s t-test; n=3).  
In summary, single GDNF-bound hydrogels does not promote cell survival. 
This inhibitory effect could be evaded by combining GDNF with FGF-2 in the 
hydrogel. Furthermore, the amount of dead cells on hydrogels is very low.  
 
To further investigate the influence of FGF2, GDNF and the combination of 
both factors bound to the hydrogel on survival of other cell types, primary fetal 
mesencephalic cells were seeded on hydrogels and cultured for 7 DIV. Cells were 
stained for neural stem cell marker Nestin, for the oligodendrocyte precursor cell 
marker Olig2, the astroglial cell marker GFAP, the marker for mature neurons MAP2 
and Hoechst 33342 to visualize cell nuclei (Figure 15). 
Immunofluorescence images show the amount of marker positive cells for 
different hydrogel modifications (Figure 15A). Cells grown on hydrogels loaded with 
FGF-2 or the combination of FGF-2 and GDNF showed similar amounts for 
investigated cell markers, whereas cells on GDNF loaded hydrogels exhibited a slight 
different marker expression.  
The quantitative analysis of the surviving cell types on hydrogels are displayed 
in Figure 15B. Cells grown on hydrogels loaded with FGF-2, GDNF or the 
combination of both factors were similarly positive for the neural stem cell marker 
Nestin (FGF-2: 16±4%; GDNF: 14±7%; FGF-2+GDNF: 13±2%; F-value 0.117, 
P>0.05, ANOVA; n=3). Also the amount of MAP2 positive cells was investigated to 
be equal for every hydrogel setting (FGF-2: 4.3±0.4%; GDNF: 19±10%; FGF-
2+GDNF: 5.8±1.5%; F-value 1.927, P>0.05, ANOVA; n=3). Tremendous differences 
were observed regarding the percentage of Olig2+ and GFAP+ cells grown on 
hydrogels loaded with different growth factors. A significant increase in Olig2+ cells in 
respect to total cell number were observed on hydrogels loaded with FGF-2 (27±5%, 
F-value 17.898, P<0.005, ANOVA; n=3) and FGF-2+GDNF (16±3%, F-value 17.898, 
P<0.005, ANOVA; n=3) compared to GDNF loaded hydrogels (0.6±0.4%, n=3). In 
contrast to that, a significant higher proportion of cells were GFAP+ on GDNF loaded 
hydrogels (9.4±1.9%; F-value 17.107, P<0.01, ANOVA; n=3) compared to cells on 
FGF-2 and FGF-2+GDNF loaded hydrogels, respectively (FGF-2: 0.9±0.1%; FGF-
2+GDNF: 1.6±0.4%, n=3).   
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Taken together, these findings demonstrate that the survival of distinct cell 
types is dependent on the growth factor which is loaded to the hydrogel.  
 
 
Figure 15: Influence of FGF-2 and GDNF loaded hydrogels on survival of different cell 
types of primary fetal mesencephalic cells.  
Cells were isolated and seeded at a density of 2,500 cells per mm2 on hydrogels with 
different modifications. (A) Representative fluorescence images were observed with staining 
for Nestin, Olig2, MAP2, GFAP or Hoechst 33342 after 7 DIV. (B) Quantitative analysis of 
cell types in respect to total cell number. Scale bar, 50 µm. Data are expressed as mean ± 
S.E.M. * - P<0.05, ** - P<0.01, *** - P<0.005, ANOVA; n=3. 
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3.2.7 Fetal primary mesencephalic cells express MMP2 and migrate into 
cleavable starPEG-heparin hydrogels 
After studying interactions of midbrain-derived cells with the biohybrid hydrogel in 
two-dimensional cell culture studies, further investigations towards a three-
dimensional growth of cells within a biomaterial has to be done in terms of in vivo 
applications. Recently, polymer hydrogels were developed containing cleavable 
peptide sequences allowing a degradation of the matrices upon enzymatic activity of 
cells. Matrix metalloproteases (MMPs) are cell-released enzymes attracting special 
attention due to their importance in cell-mediated ECM remodeling during wound 
healing and tissue regeneration. Therefore, MMP-cleavable peptide sequences were 
incorporated into the starPEG-heparin hydrogel system allowing a cell-mediated 
degradation of the biomaterial. To proof that cells derived from fetal midbrain express 
MMPs and thus are able to cleave such materials, gene expression analysis as well 
as immunostainings were performed.  
For mRNA analysis, either RNA from primary fetal mesencephalic cells 
cultivated for 7 days on PDL or laminin or directly isolated RNA from mesencephalic 
tissue were harvested. Figure 16 shows the relative mRNA levels of MMP2 and 
MMP9 in mesencephalic tissue and in cells cultured either on PDL or on laminin in 
respect to the housekeeping gene (hydroxymethylbilane synthase – HMBS). The 
mRNA expression levels of MMP2 and MMP9 in mesencephalic tissue were found to 
be very low compared to the HMBS (0.5±0.1 and 0.6±0.1, respectively; n=3). 
Although a similar mRNA expression of MMP2 could be achieved when cells were 
cultivated on PDL (1.0±0.2; F-value 4.549, P>0.05, ANOVA; n=3) or laminin (1.1±0.1; 
F-value 4.549, P>0.05, ANOVA; n=3), no expression of MMP9 were detectable under 
culture conditions (F-value 55.358, P<0.005, ANOVA; n=3).  
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Figure 16: Relative mRNA levels of MMP2 and MMP9 in mesencephalic tissue and in 
vitro.  
RNA was isolated either directly from mesencephalic tissue or after cell cultivation for 7 days. 
Data are plotted in respect to the housekeeping gene HMBS. Data are expressed as mean + 
S.E.M. *** - p ≤ 0.005, F-value 55.358, ANOVA; n=3. 
 
To investigate the expression of MMPs on protein level primary fetal 
mesencephalic cells were cultured for a period of 7 days on PDL and laminin. Later, 
cells were stained for MMP2 or MMP9 and the marker for dopaminergic cells TH in 
order to proof their ability to cleave starPEG-heparin hydrogels containing MMP-
cleavable peptides. Cell nuclei were counterstained with Hoechst 33342. Figure 17 
illustrates the immunostaining for MMP2, the marker for dopaminergic cells TH and 
Hoechst. Interestingly, not all Hoechst+ cells were also positive for MMP2 in both 
conditions. Furthermore, a co-labeling of MMP2 with TH could be shown, indicating 
the ability of dopaminergic cells to produce enzymes degrading ECM or ECM related 
peptides. For MMP9 no immunostaining either on PDL or on laminin were obtained. 
Taken together, these investigations on protein level proof the results obtained from 
mRNA analysis and let assume that cells are able to cleave starPEG-heparin 
hydrogels containing MMP sequences by the release of MMP2.  
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Figure 17: Immunoreaction of primary fetal mesencephalic cells grown on PDL or 
laminin to the matrix metalloproteinase 2 (MMP2).  
Cells were isolated and seeded at a density of 2,500 cells per mm2 on PDL or laminin. After 7 
DIV cells were stained for Hoechst 33342, MMP2 and dopaminergic cells (TH). Scale bar, 50 
µm. 
 
To investigate, whether primary fetal mesencephalic cells are able to degrade 
hydrogels containing MMP-cleavable peptides cells were isolated and seeded with a 
density of 2,500 cells per mm2. As comparison the same quantities of cells were also 
placed on non-cleavable hydrogels. Additionally, the gels were loaded with 1 µg/ml 
FGF-2 and GDNF. The 3-dimensional migration into hydrogels containing 4 µg of the 
cell adhesion molecule RGD was analyzed at two different time points (1 DIV, 5 DIV) 
(Figure 18). After 1 DIV and 5 DIV cells were stained for Hoechst 33342 and 
phalloidin, a mushroom toxin binding specifically to F-actin. Samples were 
investigated using confocal laser scanning microscopy performing z-scans. The 
invasion depth was determined with the software of the microscope.  
Figure 18A displays the 3-dimensional migration of phalloidin-stained primary 
fetal mesencephalic cells after 5 DIV cultured on non-cleavable and cleavable 
hydrogels. Cells grown on cleavable hydrogels showed a higher migration compared 
to those cultured on non-cleavable gels.  
The measurement of the invasion depth after 1 DIV showed no differences 
between cells grown either on non-cleavable (19.9±0.5 µm; P>0.05, Student’s t-test; 
n=3) or cleavable hydrogels (18.3±1.0 µm; P>0.05, Student’s t-test; n=3) (Figure 
18B). After 5 DIV a significantly higher penetration of cells into hydrogels containing 
MMP-cleavable sequences (26.9±2.0 µm; P<0.05, Student’s t-test; n=3) compared to 
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hydrogels without MMP-cleavable sequences (17.6±0.7 µm; P<0.05, Student’s t-test; 
n=3) were obtained.  
In these initial studies the ability of primary fetal mesencephalic cells to 
degrade starPEG-heparin hydrogels containing MMP cleavable sequences were 
demonstrated. These findings clear the way to perform further studies with MMP 
cleavable hydrogels in a more advanced three-dimensional cell culture system and 
for a further use for tissue remodeling in vivo. 
 
 
 
Figure 18: Migration of fetal primary mesencephalic cells grown on cleavable and non-
cleavable starPEG-heparin hydrogel.  
Cells were isolated and cultured for up to 5 days on cleavable and non-cleavable hydrogels 
containing. (A) Representative cross-sectional images illustrating the 3-dimensional cell 
migration of into cleavable and non-cleavable hydrogels containing 4 µg RGD after 5 DIV. (B) 
After 5 DIV the quantification of the invasion depth illustrates the ability of fetal primary 
mesencephalic cells to degrade hydrogels containing 4 µg RGD and MMP-cleavable 
sequences compared to cells grown on non-cleavable hydrogels with the same RGD 
content. Data are expressed as mean + S.E.M. * - P<0.05, Student’s t-test; n=3.  
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4.  Discussion 
 
4.1  Cell adhesion mediating peptide RGD promotes neurite 
extension 
As survival, proliferation, differentiation, migration and process extensions of nerve 
cells are affected by ECM compounds [123, 125, 127-129] their influence on primary 
DAergic neurons has not been studied yet. Hence, the influence of several ECM 
components and the cell adhesion mediating peptide RGD on axo-dendritic 
outgrowth of DAergic neurons were studied in this work. This included the analysis of 
the number of neurites extending directly from cell soma (primary neurites) indicating 
a primary branching capability, the number of all neurites indicating a branching 
capability of a complete neuron, and the length of neurite extension suggesting a 
possible role in promoting neurite elongation.  
Tropocollagen I, a pro-form of collagen I influenced the primary branching 
capability of DA neurons significantly. 11% more primary neurites were obtained in 
respect to PDL meaning that tropocollagen enhance the number of neurites 
originating from the cell soma. Furthermore, fibronectin and the integrin binding 
sequence RGD boosted the neurite length of DAergic neurons at about 42% and 
69%, respectively. So far, promoting effects of fibronectin and RGD on neurite 
extension was shown for several other nerve cell types [169-172]. Taken into 
consideration that ECM molecule influences many cellular functions, a cell-matrix 
interaction via the cell surface receptors integrin could be responsible for the higher 
branching on tropocollagen I and the promoting effect of the neurite length on 
fibronectin and RGD [173].  
In respect to the aim of the study to design a biomaterial which can promote 
beside cell survival and differentiation the neurite length of DAergic neurons, the 
synthetic peptide RGD was subsequently bound to the hydrogel which was used for 
further studies in this work.  
 
 
 
Discussion 
___________________________________________________________________________ 
___________________________________________________________________ 
 
- 75 - 
4.2 StarPEG-heparin hydrogels function as an efficient storage 
and delivery system for FGF-2 and GDNF 
Besides serving as cell carrier a biomaterial should be able to deliver factors 
promoting cell survival, differentiation and axo-dendritic outgrowth for integration of 
the transplant into the host brain circuitries. Since PEG hydrogels offer a high 
biocompatibility [154] and are tunable in their mechanical characteristics and 
biomolecular functionalization [151], they are of major interest for tissue engineering.  
Before analyzing the influence of modified starPEG-heparin hydrogels 
promoting cell survival and axo-dendritic outgrowth, their capability to function as 
storage and delivery matrix for FGF-2 and GDNF and their combinations was 
investigated. Uptake and release studies of FGF-2 and GDNF by the starPEG-
heparin hydrogel system were analyzed using ELISA. This polymer system utilizes 
the affinity of growth factors to heparin through electrostatic interaction between the 
negatively charged N- and O-sulfated groups of heparin to lysine and arginine 
residues of FGF-2 and GDNF [148, 149]. The large excess of heparin in the hydrogel 
and the ability of each heparin molecule to interact with several cytokine molecules, 
as reported for FGF-2 [174], allow the immobilization of large quantities of growth 
factors as well as their co-immobilization. In this work similar quantities of growth 
factors were immobilized independent whether one or even two factors were 
simultaneously loaded to the hydrogel suggesting that both factors do not influence 
each other while penetrating into the network.  
The amount of immobilized protein showed for single factors and their 
combinations similar results independent which factor was loaded. Immobilization of 
lower quantities revealed the expected results for a lower protein amount but different 
protein amounts were obtained for FGF-2 and GDNF. This may be explained by the 
instability of FGF-2 [175]. 
The release of both proteins showed the expected burst release by the 
starPEG-heparin hydrogel system within the first 24 hours as previously reported 
[156]. Such burst characteristics can be caused of surface effects [176]. However, 
within the first 24 hours ~ 95% of the complete released protein amounts were 
delivered continued by a slow release for the following 6 days. After seven days, 
nearly similar protein amounts were released for FGF-2 (~ 21%, 53 ng) and GDNF (~ 
18%, 47 ng) even though FGF-2 exhibit a higher heparin binding affinity (23 nM) 
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[177] compared to GDNF (100 nM) [149]. But the larger protein size of GDNF (2x15 
kDa) compared to FGF-2 (17 kDa) may hinder the protein to be released by the 
hydrogel. This may clear a possible higher release of GDNF due to its lower affinity to 
heparin. Furthermore, the independent delivery of two growth factors simultaneously 
could be demonstrated. For both proteins similar quantities of protein were released 
after 7 days independent whether a single factor or in combination was immobilized 
FGF-2 single: ~ 21% and in combination: ~ 20%; GDNF single: ~ 18% and in 
combination: ~ 15%. Hereby, it has to mention that an amount of ~ 80% still remains 
in the hydrogel. In other reports a delivery of ~ 40% of the immobilized GDNF from 
PLGA microspheres were observed in a comparable time frame [96, 97]. This 
difference may occur due to the use of a complete different delivery system as well 
as delivery conditions.  
Taken together, the quantities of single released protein were much higher as 
observed by Zieris A and co-workers [156]. This could be explained by the use of 
serum-free medium for their release studies. Zieris A and co-workers could also show 
that the amount of released FGF-2 under serum-free conditions of ~ 1% FGF-2 could 
be increased to ~ 10% by adding 0.1% BSA to the medium [157]. In this work, 
medium was used containing 10% FCS leading to a quantified protein amount of ~ 
21% FGF-2. The much higher amount of serum proteins in the medium could be a 
reason for the higher quantities of FGF-2 detected in this work. Furthermore, the 
release of GDNF from hydrogels in serum and serum-free medium were studied to 
investigate the amount of released GDNF in case of NSC cultivation, where serum-
free medium is applied. Under serum-free conditions ~ 2% GDNF were released 
compared to ~ 18% in serum medium. These findings are in consistence with the 
data observed for FGF-2. Possible reasons for the higher protein amount in serum 
medium could be most likely explained by the reduction of heparin – growth factor 
interaction and the subsequent replacement of growth factors by serum proteins 
[178].  
To investigate whether the whole amount of protein was detected by the 
ELISA and thus proof the efficiency of this method, FGF-2 and GDNF were added at 
a defined concentration in medium containing 10% FCS, similar to the conditions 
used for analyzing the release profile of the hydrogels. Although the same protein 
amounts were dissolved in the medium, different quantities of protein were detected 
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with a 2-fold less efficiency for FGF-2 compared to GDNF. Reasons for that could be 
that the immobilized protein was not used from the same company like the ELISA kits 
which show probably different affinities of antibodies to proteins from other 
companies. Moreover, ELISA kits from different companies had to be used. Finally, 
as reported for FGF-2 [175] fast protein degradation may take place, too. To filter out 
all inconsistence, the data were corrected with the factor obtained from the efficiency 
studies to come closer to the real protein amounts. But still, in this work, slightly 
higher amounts of released FGF-2 were detected in all conditions which are again 
explained by a faster degradation of FGF-2 during the ELISA procedure.  
 
4.3 Effects of cross-linking degree and biomolecular 
functionalization of starPEG-heparin hydrogel on fetal 
mesencephalic neural stem cells behavior 
It has been shown that NSCs respond to mechanical properties, more precisely a 
higher substrate stiffness supports NSC survival [142, 179, 180]. In concordance to 
these studies, higher cell survivals of NSCs were obtained in this work for more 
cross-linked hydrogels with higher substrate stiffness for unmodified and 
functionalized materials. Furthermore, biomolecular functionalization of hydrogels 
with RGD, FGF-2 or the combination of both compounds showed different cell 
survival rates and cell morphologies indicating the existence of different cell types on 
hydrogel modifications. Additionally, cell attachment and colony outgrowth was only 
initiated by RGD on hydrogels. This confirms earlier studies on NSCs grown on RGD-
modified polymer networks [181, 182]. Immunostainings verified these speculations 
by revealing more differentiated cells on RGD modified hydrogels, whereas on FGF-2 
releasing gels more undifferentiated cells survived. This finding is of great interest in 
case of future transplantations of FGF-2 loaded hydrogels in combination with NSCs 
into the brain: The release of FGF-2 may support NSC propagation at the 
transplantation site by overcoming microenvironmental cues of brain tissue being a 
strong inducer of differentiation [183, 184]. Moreover, survival/proliferation of NSCs 
was increased on FGF-2 loaded hydrogels compared to unmodified and RGD-
modified hydrogels. For the combination of RGD and FGF-2 a tremendous increase 
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in cell survival was found. In both cases the crucial effects of released FGF-2 on NSC 
proliferation was demonstrated [21]. 
 
4.4 Biomolecular functionalization of starPEG-heparin hydrogels 
differentially influences behavior of various cell types in 
primary mesencephalic cultures 
Isolated primary fetal mesencephalic cells exhibit a mixture of stem/progenitor cells 
and differentiated cells. Cultivation of primary cells under culture conditions using 
10% FCS leads to cell differentiation [185], whereas FGF-2 released by hydrogels 
may have a proliferative effect on remaining stem/progenitor cells [21]. The survival 
of primary cells grown on FGF-2 loaded hydrogel with highest cross-linking degree is 
influenced by mechanical properties contrary to NSCs. On this gel type only few cells 
survive, which is in consistence with a previous report by Saha K and co-workers 
[179]. Furthermore, primary cell attachment and colony outgrowth were obtained by 
any functionalization of the hydrogel, whereas NSCs spread only on RGD bound 
hydrogels. A reason for the diverse cell survival of NSCs and primary cells might be 
the different expression of integrins, the cell adhesion receptors [186].  
The quantitative analysis of the total cell number of fetal primary 
mesencephalic cells on hydrogels with different cross-linking degrees and 
biomolecular functionalization revealed only a low cell survival on plain gels due to 
the absence of any factors promoting cell viability or cell adhesion. Slightly higher cell 
survival was obtained on RGD modified hydrogels with intermediate cross-linking 
degree. Immobilization of FGF-2 to hydrogels boosted cell viability ~ 70-fold in 
average compared to pure gel. This could be explained by the proliferative effect of 
FGF-2 [21]. Recently, the supportive effect of PEG/collagen polymer immobilized with 
FGF-2 on neural cells was also demonstrated [187]. Notably, the cell survival was 
dramatically reduced on hydrogels with highest cross-linking degree and FGF-2 
immobilization indicating an inhibitory effect of the material stiffness [179]. With the 
addition of RGD, these negative effects could be compensated and a similar cell 
survival compared to lower cross-linked gels was observed. Similar to the total cell 
number, FGF-2 and RGD+FGF-2 also promote the survival of mature neuronal cells. 
Only very poor neuronal cell survival was achieved on pure and RGD modified 
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hydrogels. The investigation of the survival of DAergic cells revealed complete 
different results. RGD modified hydrogels showed the best cell survival at low and 
intermediate cross-linking degree. The loading of FGF-2 to the intermediate hydrogel 
caused even a significant lower survival of dopaminergic cells suggesting no 
supportive effect of FGF-2. To conclude, the cell survival is massively influenced by 
synergistic physical and biomolecular cues of the hydrogel.  
Furthermore, the effects of chemical/physical characteristics and biomolecular 
functionalization of the hydrogel on axo-dendritic outgrowth of DAergic cells were 
studied. The primary branching of DAergic cells seems to be unaffected by physical 
and biomolecular signals, whereas the total branching is increased on intermediate 
hydrogels loaded with RGD or FGF-2. Similar to the results obtained for the total 
branching DAergic cells with long neurites were observed on intermediate hydrogels 
with RGD or FGF-2 loading. It is to mention that on highly cross-linked hydrogel 
without any modification and with FGF-2 loading only less DAergic cells survived 
which were not testable for their axo-dendritic outgrowth. Taken together, similar to 
the cell survival studies physical/chemical characteristics and biomolecular 
functionalization of the hydrogels has strong influence on axo-dendritic outgrowth of 
dopaminergic cells.  
Since GDNF is a potent survival factor for DAergic cells (Lin; Tomac; Schatz) 
this growth factor were immobilized to RGD modified starPEG-heparin hydrogels 
alone or in combination with FGF-2 and their influence on cell viability were studied 
compared to RGF+FGF-2 loaded hydrogels. Since isolated primary cells at 
embryonic stage E14 contained differentiated and undifferentiated cells, the mitogen 
FGF-2 released by hydrogels may lead to proliferation of stem/progenitor cells [21]. 
Compared to the initial amount of cells seeded at day 0 an increase of cells of 135% 
on RGD+FGF-2 loaded and of 113% on RGD+FGF-2+GDNF bound hydrogels were 
observed. These effects are mainly attributed to the release of FGF-2 from the 
hydrogels and thus proof the bioactivity of FGF-2 when released from the gel. In 
contrast to that, GDNF alone did not support cell survival resulting in a 95% decrease 
of cells compared to the starting cell density of 2,500 cells/mm2. The analysis of the 
percentage of dead cells in respect to the total cell number revealed only low 
quantities of dead cells (~ 2 – 6%) on hydrogel modifications. This led to the 
conclusion that low cell survival on single GDNF loaded gels is not related to a high 
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percentage of dead cells. This could rather be a result of low cell adhesion to GDNF 
modified gels. Since cell replacement therapies are often hampered by a low cell 
survival, an implantation of FGF-2 and GDNF loaded hydrogel could be an alternative 
option to improve cell counts after the transplantation process.  
To investigate whether biomolecular functionalization with FGF-2, GDNF and 
the combination of both factors has an effect on survival of different cell types, 
immunostainings against markers of undifferentiated and differentiated cells were 
performed. It was found that the percentage of neural stem cells (Nestin+) as well as 
of mature neuronal cells (MAP2+) were equal in respect to the total cell number in 
any tested condition. In contrast to that, the survival of Olig2+ and GFAP+ cells seems 
to be affected by the growth factors which were released by the hydrogels. FGF-2 
loading caused 45 times more Olig2+ cells compared to GDNF loading alone, 
whereas a combined incorporation of FGF-2 and GDNF led to 26 times more Olig2+ 
cells. The increased amount of oligodendrocyte precursor cells is either attributed to 
their higher survival or to the proliferative effect of FGF-2 [21]. Contrary results were 
obtained for the quantity of GFAP+ cells at each hydrogel modification. In comparison 
to hydrogels loaded with FGF-2 alone and the combination of FGF-2 and GDNF, 10-
fold and 6-fold more GFAP+ cells were quantified on GDNF loaded gels, respectively. 
To conclude, the biomolecular functionalization of the hydrogel with FGF-2 or GDNF 
decides on the survival of a certain cell type.  
 
4.5 Enzymatically degradable starPEG-heparin hydrogels allow a 
localized cellular invasion of primary fetal mesencephalic cells 
For a three-dimensional reconstitution of tissues or tissue systems such as the 
central dopaminergic nigro-striatal pathway in the brain, the implanted biomaterial 
has to offer various physical and biochemical cues to serve as cell carrier releasing 
factors that support the regenerative process. Moreover, the transplanted cells 
should be able to degrade and invade the biomaterial and send axons towards the 
target region. During CNS development and throughout adulthood matrix 
metalloproteinases (MMPs) play a pivotal role in cell migration, axonal outgrowth, 
neuronal differentiation and plasticity [110, 188]. The main functions of these 
proteolytic enzymes are the remodeling and degradation of the ECM. In order to 
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develop a biodegradable biomaterial, MMP cleavable peptide sequences 
(GPQG↑↓IWGQ) were included into the starPEG-heparin hydrogel allowing a 
localized cellular invasion and a possibly elongation of process extensions into the 
biomaterial.  
In this work initial experiments to explore the effects of primary fetal 
mesencephalic cultures on MMP-degradable starPEG-heparin were performed. 
Initially, the mRNA expression levels of MMPs in primary fetal mesencephalic cells 
were analyzed to proof the ability of this cell source to cleave starPEG-heparin 
hydrogels containing MMP cleavable sequences. Thereby, the main focus was on the 
investigation of MMP2 and MMP9 expression levels. Among others, MMP2 and 
MMP9 are expressed during development of the cerebellar cortex [189]. Moreover, 
recent studies suggested the secretion of large quantities of MMP2 by NSCs [190]. In 
this work, only low relative mRNA expression levels of MMP2 and MMP9 were found 
in mesencephalic tissue. Interestingly, after cultivation of primary fetal mesencephalic 
cells for one week on substrates frequently used in cell culture (PDL, laminin); similar 
MMP2 expression levels were analyzed, whereas MMP9 was undetectable. A 
comparable result was reported for the expression of MMP2 and MMP9 in astrocytes 
[191]. The immunoreactivity for MMP2 was demonstrated for primary mesencephalic 
cells cultured for one week either on PDL or on laminin. No differences in the 
immunolabeling of cells in both conditions were observed. Hereby, it has to mention 
that not all cells showed immunoreactivity for MMP2, but a co-expression with 
dopaminergic cells could be demonstrated. As expected from mRNA studies no 
immunoreactivity for MMP9 was detected when primary fetal mesencephalic cells 
were cultivated on PDL or laminin.  
Taken together, these findings suggest the ability of primary fetal 
mesencephalic cells to express MMP2 and MMP9, but under culture conditions only 
MMP2 may facilitate the cleavage of starPEG-heparin hydrogels containing MMP 
cleavable sequences.  
To determine the potential of starPEG-heparin hydrogels containing MMP 
cleavable peptide sequences for an application primary fetal mesencephalic cells 
were cultured in an initial cell culture study for five days on cleavable and non-
cleavable gels containing RGD, FGF-2 and GDNF. In this work a much stronger 
invasion of primary fetal mesencephalic cells after 5 DIV and thus their ability to 
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cleave such biomaterials could be demonstrated compared to non-cleavable 
hydrogels. Recently, in a study by Chwalek K and co-workers a similar migratory 
behavior of endothelial cells on VEGF immobilized cleavable hydrogels could already 
be obtained after 2 DIV [168]. This led assume that the MMP expression is much 
higher in endothelial cells and/or the immobilized growth factor VEGF function as a 
stronger attractor compared to FGF-2 and GDNF. 
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5.  Conclusion and Outlook 
Several important conclusions concerning the development of a biomaterial for 
reconstructing the central DAergic nigro-striatal pathway in PD could be drawn from 
this work: 
 
1)  Firstly, the results showed for the first time that tropocollagen I, fibronectin and 
RGD influence the axo-dendritic outgrowth of primary fetal DAergic cells. 
Among those, RGD is an interesting peptide due to its ability to be bound to 
several biomaterials to mediate cell adhesion. In this work, a promoting activity 
on the neurite elongation of primary DAergic cells could be shown. So far, a 
supportive effect of this peptide on neurite extensions was observed only for 
other nerve cells [169-172]. Thus, these data suggest that cell-matrix 
interactions with RGD not only promote cell adhesion but also could exhibit 
beneficial effects on neurite length of DAergic cells.  
 
2)  Secondly, uptake and release experiments of growth factors from the hydrogel 
system demonstrated their use as efficient storage and delivery system. The 
release itself is characterized by an initial burst, which may be supportive for 
the survival of transplanted cells where a major cell loss occurs during the 
transplantation process. Furthermore, the simultaneous uptake and release of 
growth factors were demonstrated. This led conclude, that due to the high 
heparin content of the hydrogel system any soluble factor with heparin-binding 
motif can be immobilized to and be delivered by the matrix. Notably, a very 
high amount of growth factors still remain in the hydrogel and is released 
slowly over time.  
 
3) Thirdly, for tissue engineering approaches in PD using a starPEG-heparin 
hydrogel system its influence on several cellular processes has to be clarified. 
Therefore, the effects of different structural/mechanical and biomolecular cues 
on two standard cell sources for neural transplantation were evaluated. 
Depending on the material stiffness and the presence of biomolecules the 
hydrogel showed distinct growth properties of fetal mesencephalic NSCs and 
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primary fetal mesencephalic cells. This led to the conclusion that for tissue 
engineering approaches the biomaterial has to be adapted in respect of the 
used cellular source as well as the properties of the tissue which has to be 
replaced has to be taken into account. 
Furthermore, with the combined incorporation of RGD and the soluble 
mitogen FGF-2 the cell survival of both cell sources could be tremendously 
increased. These findings may be explained by the proliferative effect of FGF-
2 on both cell sources containing stem/progenitor cells [21]. Since cell 
replacement therapies for PD are often hampered by a low cell survival [192] 
and the fact that the brain is a strong inducer for differentiation [183, 184] 
these results are of quite importance. Moreover, the presence of RGD in the 
hydrogel led to differentiation of NSCs, whereas on FGF-2 releasing hydrogels 
more undifferentiated cells survived. These results are in consistence with the 
fact that ECM compounds stimulate many cellular processes such as 
differentiation [125, 127, 129] and the known mitogenic action of FGF-2 [21].  
The survival and axo-dendritic outgrowth of DAergic cells, which is the 
cell type got lost in PD, is also affected by the gel properties. RGD or FGF-2 
modification of hydrogels showed the best results for DAergic growth but are 
still not convincing due their relative low boost effect on survival and axo-
dendritic growth of DAergic cells in order to reach the striatum, the target 
region.  
Although GDNF is a potent factor for the survival of DAergic neurons 
[63, 64, 74] the release of this factor by the hydrogel showed only a marginal 
cell survival as well as a low percentage of dead cells indicating that a slight 
cell adhesion is responsible for the low amount of cells growing under these 
conditions. These results may also point out the urgent need of FGF-2 for a 
higher cell survival combined with GDNF and/or any other promising factors 
are needed in a starPEG-heparin based approach. Interestingly, the survival of 
specific cell types can be stimulated by the growth factors which are loaded. 
Thereby, a high viability of oligodendrocyte precursor cells on FGF-2 loaded 
hydrogels was predominant. This result may increase the risk for brain cancer 
where a vast majority of mitotic cells express Olig2 [193]. Furthermore, the 
tremendous effect of GDNF in combination with FGF-2 on the survival and 
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axo-dendritic outgrowth of DAergic cells could be demonstrated by a colleague 
in our lab suggesting a synergistic effect when both factors are released by the 
hydrogel. 
4) Fourthly, for a three-dimensional reconstitution of the central DAergic nigro-
striatal pathway in the brain using the “bridging” technology the biomaterial 
has to biodegradable. The enzymatic degradation of starPEG-heparin 
hydrogel containing proteolytically cleavable peptide sequences by primary 
fetal mesencephalic cells could be demonstrated in this work. Furthermore, 
the expression of MMP2 by primary fetal mesencephalic cells was shown, 
whereas MMP9 is only expressed in mesencephalic tissue. This indicates that 
besides other not evaluated proteinases MMP2 led to the cleavage of the 
hydrogels.  
 
Future research should focus on three-dimensional cell culture studies using 
starPEG-heparin hydrogels with cleavable peptide sequences. These experiments 
should be performed in a customer-made cell culture device which was designed 
according to several requirements in cooperation with Mathias Ulrich from the 
Department of Device Development and Construction at the Leibniz Institute of 
Polymer Research Dresden (Figure 19). This two-chamber device is designed to 
perform three-dimensional cell culture studies. The two chambers can collect 100 µl 
of volume and are connected with a channel for the placement of the hydrogel. The 
channel is constructed in three different lengths (2 µm, 3 µm, 4 µm) and two different 
widths. The usage of place-holders seeded in the chambers allows an unrestricted 
preparation of the hydrogel in the channels. Furthermore, the device is autoclavable 
and suitable for microscopy. Placing cells of distinct brain regions, such as 
Substantia nigra and striatum, in the chambers allows studying the three-dimensional 
cell outgrowth through cleavable starPEG-heparin hydrogels due to released 
chemoattractant factors by striatal cells. By applying gradients of signaling molecules 
to the hydrogel their ability to promote axo-dendritic outgrowth of dopaminergic cells 
in PEG hydrogels could be evaluated. Brain derived neurotrophic factor (BDNF) and 
sonic hedgehog (Shh) are promising candidates for axon guidance.  
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Figure 19: Customer-made cell culture device for three-dimensional cell culture 
studies.  
The two-chambers are connected with a channel available in three different lengths 
and two different widths.  
 
 
Furthermore, transplantation of enzymatically degradable starPEG-heparin 
hydrogels loaded with different growth factors should be performed to proof the in 
vivo applicability of the biohybrid hydrogel to treat PD. This includes stability studies 
of the transplanted bioscaffolds after remaining several months in the host brain and 
the investigation of short- and log-term effects to elucidate host-bioscaffold 
interactions. 
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6.  Abbreviations 
 
aFGF/FGF-1  acidic growth factor 
BBB   blood-brain barrier 
BDNF   brain-derived neurotrophic factor 
CNS   central nervous system 
DA   dopamine 
DIV   days in vitro 
ECM   extracellular matrix 
EDC   1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EGF   endothelial growth factor 
ELISA   enzyme-linked immunosorbent assay 
ES cell  embryonic stem cell 
FCS   fetal calve serum 
bFGF/FGF-2  basic fibroblast growth factor 
GAG   glycosaminoglycan 
GDNF  glial cell-derived neurotrophic factor 
GFAP   glial fibrillary acidic protein 
HMBS  hydroxymethylbilane synthase 
IGF-1   insulin-like growth factor 
iPS cell  induced pluripotent stem cell 
L-DOPA  Levodopa (L-3,4 –dihydroxyphenylalanine) 
LV   lentivirus 
MAP2   microtubuli-associated protein 2 
MMP   matrix metalloproteinases 
MPTP   1-methyl-4-phenyl-1,2,3,6-tetrahydropyridne 
NGF   nerve growth factor 
NSC   neural stem cells 
NT-3   neurotrophin-3 
NT-4/5  neurotrophin-4/5 
PCR   polymerase chain reaction 
PET   positron emission tomography 
PEG   poly(ethylene glycol) 
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PI   propidium iodide 
PLGA   poly(lactic-co-glycolic) acid 
PFA   paraformaldehyde 
POMA  poly(octadecen-alt-maleic anhydride) 
RCA   Radio Cooperation of America 
RGD   Arg-Gly-Asp  
SHH   sonic hedgehog 
S.E.M.  standard error of the mean 
s-NHS  N-hydroxysulfo-succinimid 
ß-Tuj1  ß-Tubulin III 
6-OHDA  6-hydroxydopamine 
TGF-ß  transforming growth factor-beta 
TH   tyrosine hydroxylase 
TIMP   tissue inhibitors of matrix metalloproteinases 
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